var title_f8_51_9008="Dx ileal pouch disorders";
var content_f8_51_9008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm of ileal pouch disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 478px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shen B, Remzi FH, Lavery IC, et al. A Proposed Classification of Ileal Pouch Disorders and Associated Complications After Restorative Proctocolectomy. Clin Gastroenterol Hepatol 2008; 6:145. Copyright &copy;2008 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9008=[""].join("\n");
var outline_f8_51_9008=null;
var title_f8_51_9009="Contents: Pregnancy complications";
var content_f8_51_9009=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pregnancy complications",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pregnancy complications",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Amniotic fluid disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14233\">",
"           Oligohydramnios",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/44/4808\">",
"           Polyhydramnios",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/22/20840\">",
"           Management of cardiopulmonary arrest in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24202\">",
"           Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/54/4968\">",
"           Prenatal sonographic diagnosis of fetal cardiac anomalies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/2/36902\">",
"           Amniotic band sequence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/0/23562\">",
"           Congenital cytogenetic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/23/28026\">",
"           Congenital diaphragmatic hernia in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42169\">",
"           Congenital diaphragmatic hernia: Prenatal diagnosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/165\">",
"           Diagnosis and management of twin reversed arterial perfusion (TRAP) sequence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/44/20169\">",
"           Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/39/12920\">",
"           Fetal ventriculomegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7386\">",
"           Genetic and environmental causes of birth defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/45/1750\">",
"           Induced fetal demise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/21/6488\">",
"           Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/40/35464\">",
"           Obstetrical management of gastroschisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38454\">",
"           Obstetrical management of omphalocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/44/32456\">",
"           Overview of echogenic masses and calcification in the fetal abdomen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/56/23431\">",
"           Preimplantation genetic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37623\">",
"           Preimplantation genetic screening (PGS) for aneuploidy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/42/10919\">",
"           Prenatal diagnosis and management of bronchopulmonary sequestration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11561\">",
"           Prenatal diagnosis and management of congenital pulmonary airway malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/44/2762\">",
"           Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12500\">",
"           Prenatal diagnosis of congenital mesoblastic nephroma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/62/34793\">",
"           Prenatal diagnosis of gastrointestinal atresia and obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/23/33141\">",
"           Prenatal diagnosis of talipes equinovarus (clubfoot)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42585\">",
"           Prenatal diagnosis of the lethal skeletal dysplasias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15737\">",
"           Prenatal sonographic diagnosis of cystic renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34247\">",
"           Prenatal sonographic diagnosis of fetal abdominal wall defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/54/4968\">",
"           Prenatal sonographic diagnosis of fetal cardiac anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/7/19574\">",
"           Principles of teratology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/46/35560\">",
"           Ultrasound diagnosis of neural tube defects",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/39/4725\">",
"           Cushing's syndrome in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37866\">",
"           Medical management and follow-up of gestational diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9210\">",
"           Screening and diagnosis of diabetes mellitus during pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fetal growth restriction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/23/22906\">",
"           Diagnosis of fetal growth restriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23994\">",
"           Fetal growth restriction: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/63/13302\">",
"           Interpregnancy interval and pregnancy outcome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10616\">",
"           Overview of causes of and risk factors for fetal growth restriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/35/22068\">",
"           Postnatal assessment of gestational age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/23/9593\">",
"           Small for gestational age infant",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fetal loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/9/1178\">",
"           Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38999\">",
"           Counseling parents after stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/6/8298\">",
"           Definition and etiology of recurrent pregnancy loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/35/1591\">",
"           Diagnosis and management of stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/3/26679\">",
"           Evaluation of couples with recurrent pregnancy loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38839\">",
"           Evaluation of stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31306\">",
"           Incidence, etiology, and prevention of stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21752\">",
"           Incidence, risk factors, and pathology of ectopic pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/49/27417\">",
"           Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/23/19834\">",
"           Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/53/5976\">",
"           Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/24/34184\">",
"           Ultrasonography of pregnancy of unknown location",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36819\">",
"           Intrauterine fetal transfusion of platelets",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13210\">",
"           Intrauterine fetal transfusion of red blood cells",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/21/5464\">",
"           Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32982\">",
"           Overview of Rhesus (Rh) alloimmunization in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/60/12232\">",
"           Prenatal management of neonatal alloimmune thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40648\">",
"           Prevention of Rh(D) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/27/3513\">",
"           Significance of minor red blood cell antibodies during pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/7/8311\">",
"           Clinical features and diagnosis of placenta accreta, increta, and percreta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/13/35032\">",
"           Clinical features, diagnosis, and course of placenta previa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/45/3800\">",
"           Diagnosis and management of massive fetomaternal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/16/19719\">",
"           Management of placenta accreta, increta, and percreta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/60/42952\">",
"           Management of placenta previa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/38/42600\">",
"           Overview of postpartum hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15465\">",
"           Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29367\">",
"           Peripartum hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/46/29417\">",
"           Placental abruption: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/54/34663\">",
"           Placental abruption: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/18/20775\">",
"           Velamentous umbilical cord insertion and vasa previa",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperemesis gravidarum",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41207\">",
"           Clinical features and evaluation of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/20/29002\">",
"           Treatment and outcome of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24037\">",
"           Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16328\">",
"           Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42841\">",
"           Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18825\">",
"           Antiretroviral medications in pregnancy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/33001\">",
"           Genital herpes simplex virus infection and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28041\">",
"           Overview of TORCH infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/29/40408\">",
"           Parvovirus B19 infection during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/63/4089\">",
"           Placental infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6087\">",
"           Rubella in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/61/4057\">",
"           Syphilis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/39/22137\">",
"           Toxoplasmosis and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33225\">",
"           Varicella-zoster virus infection in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/38/24166\">",
"           Acute fatty liver of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/37/26198\">",
"           Approach to liver disease occurring during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41207\">",
"           Clinical features and evaluation of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17897\">",
"           HELLP syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4617\">",
"           Intrahepatic cholestasis of pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malpresentation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/43/21176\">",
"           Delivery of the fetus in breech presentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/5/8281\">",
"           External cephalic version",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/8/13448\">",
"           Overview of breech presentation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple gestation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5510\">",
"           Delayed-interval delivery in multifetal pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/45/1750\">",
"           Induced fetal demise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9913\">",
"           Management of twin-twin transfusion syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/31/43511\">",
"           Monoamniotic twin pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39065\">",
"           Multifetal pregnancy reduction and selective termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27594\">",
"           Neonatal outcome, complications, and management of multiple births",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28039\">",
"           Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/28/11718\">",
"           Triplet pregnancy: Early pregnancy management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12842\">",
"           Triplet pregnancy: Mid and late pregnancy complications and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40682\">",
"           Twin pregnancy: Prenatal issues",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/53/21334\">",
"           Incarcerated gravid uterus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/58/9128\">",
"           Inter-facility maternal transport",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/37/34393\">",
"           Nonimmune hydrops fetalis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/45/15065\">",
"           Pregnancy in women with uterine leiomyomas (fibroids)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/4/44102\">",
"           Rupture of the unscarred uterus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postterm birth",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/9/16535\">",
"           Postterm pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preeclampsia and eclampsia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17832\">",
"           Abnormalities of coagulation and platelet function in preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/2/32808\">",
"           Expectant management of severe preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/44/29383\">",
"           Gestational hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17897\">",
"           HELLP syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/61/34777\">",
"           Pathogenesis of preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/13/11480\">",
"           Prediction of preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27978\">",
"           Preeclampsia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21882\">",
"           Preeclampsia: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41609\">",
"           Prevention of preeclampsia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Premature rupture of membranes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4407\">",
"           Management of premature rupture of the fetal membranes at term",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27353\">",
"           Midtrimester preterm premature rupture of membranes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32393\">",
"           Pathogenesis of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/31/15866\">",
"           Preterm premature rupture of membranes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preterm birth",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/55/31610\">",
"           Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4457\">",
"           Cervical insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/51/15159\">",
"           Fetal fibronectin for prediction of preterm labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35674\">",
"           Inhibition of acute preterm labor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/63/13302\">",
"           Interpregnancy interval and pregnancy outcome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/36/24135\">",
"           Management of pregnant women after inhibition of acute preterm labor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27353\">",
"           Midtrimester preterm premature rupture of membranes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/30/5608\">",
"           Overview of preterm labor and birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32393\">",
"           Pathogenesis of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/0/6153\">",
"           Physiology of parturition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/6/2154\">",
"           Pregnancy outcome after assisted reproductive technology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/31/15866\">",
"           Preterm premature rupture of membranes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11994\">",
"           Prevention of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/33/5657\">",
"           Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/3/35898\">",
"           Risk factors for preterm labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/49/32532\">",
"           Transabdominal cervical cerclage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/42/37544\">",
"           Transvaginal cervical cerclage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/33/21017\">",
"           Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33479\">",
"           Acute kidney injury (acute renal failure) in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical disease and trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8727\">",
"           Laparoscopic surgery in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15482\">",
"           Management of pregnant women undergoing nonobstetric surgery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29657\">",
"           Dermatoses of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44041\">",
"           Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41000\">",
"           Obstetrical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22569\">",
"           Trauma in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-928E6C692B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_51_9009=[""].join("\n");
var outline_f8_51_9009=null;
var title_f8_51_9010="Moyamoya with intraventricular hemorrhage";
var content_f8_51_9010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    A 22 year old woman with moyamoya disease and sudden severe headache",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Non-contrast CT scan of the brain reveals blood in the frontal and occipital horns of the left lateral ventricle (white arrows).",
"    <br>",
"     (B) Cerebral angiogram (lateral projection) demonstrates total occlusion of the left internal carotid artery and collateral flow from the external carotid system.",
"     <br>",
"      (C) Selective angiogram shows severe stenosis of the distal part of the right internal carotid artery. Note the collateral vascular networks around the stenotic area (black arrows).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Nijasri Suwanwela, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9010=[""].join("\n");
var outline_f8_51_9010=null;
var title_f8_51_9011="Acyclovir (topical): Pediatric drug information";
var content_f8_51_9011=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acyclovir (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/27/1460?source=see_link\">",
"    see \"Acyclovir (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/60/40899?source=see_link\">",
"    see \"Acyclovir (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7908397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7908398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10456705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10456711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/27/1460?source=see_link\">",
"      see \"Acyclovir (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cream: Herpes labialis (cold sores): Children &ge;12 years and Adults: Apply 5 times/day for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ointment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Genital HSV, immunocompromised: Adults: Initial episode:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     \" ribbon of ointment for a 4\" square surface area every 3 hours (6 times/day) for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mucocutaneous HSV, nonlife-threatening, immunocompromised: Adults:  Ointment:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     \" ribbon of ointment for a 4\" square surface area every 3 hours (6 times/day) for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7908562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 5% (2 g, 5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 5% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 5% (15 g, 30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7912809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes cream",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11277504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only; do not apply to eye, inside the mouth or nose, or on unaffected skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Apply layer of cream to cover only the cold sore or cover the area with symptoms; rub cream in until it disappears.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Use a fingercot or rubber glove when applying ointment to prevent autoinoculation of other body sites or transmission of infection to other persons.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10456709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream: Store at &le;25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F) in a dry place.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10456706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical (cream): Treatment of recurrent herpes labialis (cold sores) (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical (ointment): Management of initial genital herpes and in limited, nonlife-threatening mucocutaneous HSV infections in immunocompromised patients (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7908396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acyclovir may be confused with ganciclovir, Retrovir&reg;, valacyclovir",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zovirax&reg; may be confused with Doribax&reg;, Valtrex&reg;, Zithromax&reg;, Zostrix&reg;, Zyloprim&reg;, Zyvox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Opthavir [Mexico] may be confused with Optivar brand name for azelastine [U.S.]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7908486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dermatologic: Burning, itching, mild pain, pruritus, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10456707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acyclovir, valacyclovir, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F11277485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only to the lips and face; do not apply to eye or inside the mouth or nose. Treatment should begin with the first signs or symptoms. Use with caution in immunocompromised patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11277484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Physical contact should be avoided when lesions are present; transmission may also occur in the absence of symptoms. Treatment should begin with the first signs or symptoms. Acyclovir ointment should not be used for prevention of recurrent HSV infections.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7912821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7912816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7912817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. When administered orally, acyclovir crosses the placenta. Refer to the Acyclovir, Systemic monograph for details. The amount of acyclovir available systemically following topical application of the cream or ointment is significantly less in comparison to oral doses.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10456710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and by incorporation into viral DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10456712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Poorly absorbed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15937 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9011=[""].join("\n");
var outline_f8_51_9011=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908397\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908398\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456705\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456711\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908562\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912809\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11277504\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456709\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456706\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908396\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908486\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456707\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11277485\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11277484\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298683\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912821\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912816\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912817\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456710\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456712\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15937\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15937|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"UTD.htm?17/42/18081?source=related_link\">",
"      Acyclovir (ophthalmic): International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/40/37512?source=related_link\">",
"      Acyclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/48/38660?source=related_link\">",
"      Acyclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/37/2649?source=related_link\">",
"      Acyclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/27/1460?source=related_link\">",
"      Acyclovir (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/60/40899?source=related_link\">",
"      Acyclovir (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_51_9012="Chest CT cryptococcal pneumonia";
var content_f8_51_9012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse CT scan in 46-year-old woman shows several nodules in the lung bases (7-mm-thick section)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Most of the nodules have smooth margins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lindell, R, Hartman, T, Nadrous, H, et al. Pulmonary Cryptococcosis: CT findings in immunocompetent patients. Radiology 2005; 236:326. Copyright &copy; 2005 Radiological Society of North America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9012=[""].join("\n");
var outline_f8_51_9012=null;
var title_f8_51_9013="Atazanavir: Patient drug information";
var content_f8_51_9013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Atazanavir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     see \"Atazanavir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/7/7290?source=see_link\">",
"     see \"Atazanavir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Reyataz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Reyataz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atazanavir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat and do not have a pacemaker, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids or didanosine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a hormone-related kind of birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most often taken with at least 2 other drugs. Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11187 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9013=[""].join("\n");
var outline_f8_51_9013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855135\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018554\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018556\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018555\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018560\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018561\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018563\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018558\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018559\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018564\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018565\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=related_link\">",
"      Atazanavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/7/7290?source=related_link\">",
"      Atazanavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_51_9014="Seldinger technique";
var content_f8_51_9014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Seldinger technique for central venous access",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The needle, attached to a syringe, is inserted into the femoral vein. Once the needle is through the skin, the plunger of the syringe is gently pulled back. The needle is in the vessel when blood flows freely into the syringe. B) The syringe is removed and the flexible end of the guidewire is inserted through the needle into the vessel. C) The needle is removed, leaving the guidewire in place. The catheter is advanced with a twisting motion over the guidewire into the vessel. The guidewire is then removed as the catheter is held in place. D) The catheter should flush easily with fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9014=[""].join("\n");
var outline_f8_51_9014=null;
var title_f8_51_9015="Stomatocytes";
var content_f8_51_9015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stomatocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 244px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD0AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1q2fZqMiyDAJABz261uRsgj3MRwMEE9PasPVbGZJN8eS6YGB/EPUVn/bpkIUh8kheR0968+OKlSj7KS1R9dKj7dKUWT6r8z4iOMsDnrkd66mwVvIjDAE7FznI7fr2rB0uwluZhLcIwiB6Efe+ldSiFVHY+n9K7MJRdODc92c+MqJJU10F4AzgjjuP50hQYyex59R/nNSoBuGc4qRgWHI9yB/jXUea5WKx+ZicjB4pGmjhTdI4HHfvT3GxXyOB2rltQuHuJ/LXlBkVzV6zh7sdzooUfbO3Q131m3VsAFgOuDVi21O2uG2BgpPZ+M/nXMxpIH2qoIzz7VKbaTGSoZPUdRWMalZavU65YSla1zscjOOKjmQuwZXZSOmO4/yKz9Au2l3Ws/LIuUPfHpWqRyMZx29q7Yy5lzHmTg6U+VmFqGnywTG5tV3RM25lAz5bfQdqpS3skqFDg54IPf2NdNPPHbxtJI4UDn6n0rN/tvcxZbQMw6EgZ/lXNUjTUra/I66VWcl8N7ddito+ltLcpc3CtsU7xuGN57Ae1M1i4+0X0kKYSOM/OR/E3qa2rPU47l1WYeTLkfK/THsa527jNvf3asuGLlhjpyaVZJRSjsXSlKdVuotUtDb06ztzYAyRkhz1zgj6Y/rUV7o8QjZ7ZiU/uN/DmpdImElns5DR8YHpV+AlZAv8DDaRjrXSrSicsqlSnNtM4/Tbma21AW0rZtZDgZ42H1FdlAGSIbyC4znjHeuW1JVFzMm3DK2R611gl822t5j950ViPfFZYdNNpmmNfMoyS3AuGzlsnrisvxErjSzt6GRQ3H161oKRuIJ9/qaWeNLiBreQcMPvY6HtmuiSurHJTl7Oal2Of0+ITbVGPbI7YrWGmwDGTubHPSsZzLZzCOYMj9ieh/yKmfUpQuARk9xWCl7PRo7qkKk3eD0Lmp/Z7e1MaIu5uvt9aZ4bhb7DKSAEMxwc9eOfwrOjE99KscQLSMeS3QD1rT1rOn6PDa2xzubYX6E9z+tCbvzsmUbRVG+smVLzWCsrpYwrJt43MeCfaqcOsX4VXlt0PQlT1HtkZH49KdZRdFwMdsdKvTWTpEXdWAxySKw5JVPeubNUafutFzSryC+cyI7xzouxod3y4znOO57Z9DV/H944x6c1xzu9rcRXEJCODyc/kPxrscqUVl5VhkH0B6VrQm3eMjkxVFU2nHZlHXYfM01hGo+VhkD054rnRERgHIGemMDFdRqd3HYWTO/JcFVU9/WudgtTmSW2jEglIZ3jXknGAT74AH4VOIipNJbm+Ek1Td9iWzvYLSPAs9zn77vySPb0FUdbvxcq8ghCKv8AAoySPbFSvG7NtZZcHOBtySacbBo1Nxcfu1XlVJwW/wABWXLVStsjqgqcJ8739TftrfZYQQvkEIvIYg569RzUj+Xv6RyA8Yb36/j7VV0S+F/Ccn96jbXwfy/SrQgWKcyqQcjgZ7/4V10WpQVuh5k04zanuYl54Us57rzkl8hGcySRhCxPGOOfp2/CpWhg0rTJrizI8oruReMnI9f1rU42naNmDnePvZ9c/wCPesrXCbbQ1V3Mzr0OwLvbk8hRge+BjvW0EpTV0bRrVJ2hOV12PCPH120/iSG3uA/2VSFLL8qk9WP1PrXP6pYMJlbT43jthGFT5sgfj3NaMDLeafqU1zzcyyFm3MSDjjOe2Pwp2gxu2h3EpdPJjJjUy4C8+5/Cvq4pQivLQ+up/u4JLoU7i4b7HaQW5jaUcsCMHHqT2qLXHuVKw2TDYihWCc5zVi70ER2MrvIEmZyCc4UYHAH+NMsbAxsqtIjKwyCnJJAq0orVGikt0dR8OJVttQsLe7hywkLIZBkxtggEfgSM+9e77FktxnDBgDjFeBeD4nfXIonV8xyDqP8APpX0Ha4ECAY4xuycYrwsyio1U+p8/nOk4yW5514qi8iS+mfjggHrnOAP50V1nivRTq1lIsLBZwMoSOMjlc/jiivnMfl8sTU9pD+vxO3A4+l7Jc7SfmaV1D5kUijqRhcj7pxwajSFWCkbSQedyA5+lWZMEMzgKMEcnjFQ/abdfkVlwOyjj9K7HOKerPnYuVrIl24I67h0yOlR3V2ltGWIYsBwB3p5dQm5Sz/7oyTXPa5I/mqPmVcYKk9O5/H6Vhi68qcUo7suhS9rOzJzrTvNtTB+gxV611hW+W6UqrHG7GRj3qlpllDdYUoAw+bdt5HtU+oWYt08xCSvSso+1px53K6N6kaDl7O2po3zKLV3jOUK7lI6YrndFe3mc+aepPbFaGjrlprYjCvmQDPcdf0/lWItu9ldywPkFWO33HUYrSpPlnGolui6FNJSp31Oujgt1OViU/XnFJfy+VDtQIqchgV56cY/GufW9nj/ANXI2BxyabLczXLKCxY/1qp1nNckVqZrCS5ryehb0Tc2sRbegJz9MV0LMVVzjG3k8Y4qjo9j9ji8+bHnOOB/dHv71Zu4BPG+AfNEbKnPAJHPHTPGK25HCnyrdHNiJxqVNNtinYvDqLSfaM5PCKDjio3tEtZcuRs6rn+Ksq0kZdpB2lDWrc3CXUETuBuHXnr71kppx80dE6coTsnox13c217bO1uRHNF820/0qPV0NzDaaiq7wU8uYjsRVCTBkLIBkHoD09v1roNDj8vTAJRuWVicNzlaqF6l+YmpaglKP9X3MCO5ktnPlYKtjP4Vtadd71LSuo2c+9Q3miRynfYSquc/IxyPwNVho+oYwAgHPzb8ZpRhOD0HOVGrHez89ytes15fyLECxkk4A966ooIkSJclUUKPfFU9L0xLH95IwkuD930T6Veb6jn2renDlRyYirGbUYbIjRcHIwGPJ4p2449fXtRtUMOQO3NOCEYIByOhqnpuc7ZHcBZUxLGJRjgGqq6bZA5Eb4HvxVzg4YZwe9MfgcgdccChO+xcZSjpF2EiWKGNkt0Eanrjk/nWZ4m3GxgkXkJIQefatEZ64YZOBx196WWFLiGSCQEBhxnkZpNXVi6cuSamzA0y6VJV3AdQa6GQfaYCoJAbnJrjpFmsZzFNH8w5Ugjp7Zq9DrMiR+WNy8Z5XoK5IzdJ8sjur4ZzanTKerfut+455PHFdXbsxs7YdWEagn04rlYLaTVL1U+9CDukZhwBXW5BJ2jaBwAfaqoxfM5EYxpRjDqjB8TSE6jFGx+SOL8ie+KZo9yLe5VTJ5avx7E9h9af4sh2XdvccBHTbz6j/wDXWJIu9CWOe2Pf+tYV7xqXOmhTjUoRj0sdxFvGSCMk59zXNa2G80h2z7Dk1Fp+s3FqgRiJlwcB+ox71manefbbwSGNTNEA2cH5Fbrg987en51bxKcNVqTh8JUp1W3sanhDK6lOgBCmLcQOOQRit+5mJmeKLlhwxzwKx/BsJUXd/KvylfLT3A5P+FT6VdRztP5pw7NuznrzVYf93DmfVmeKjz1pSXSw+S3nezZiDHOFyyo2QPxrn21aW+tptPv3CXBOYnAxu9vyrtFjVcADap6+lch4k002t6WTnPII6+oreomo88XqtSsJKFWTpz+R4p4i0260a5kt5HBjMhyMHaRn5Tn1x1HSqdvHLpl80rGKVBCyglspgnP3Rwa9S1rS7PWIJHuLYtIoyXB+ZTnkgelYtz4GhaGTyJ1VZlAUOM/L349K+jwuY08RSTlv19T3oYuKjyVNzz2VZtUvUuZT/oisIVCqflB7cdBkdTWv9suY7yB7W2KwKgVP3Y598k11Vt4Fu5N9pbSWyxAYaTcVAX0x3q/Z+AJ7preJZvNgt+OQVUgHoPwzxXVPFUVu0XLGUY7sT4faRJf6z9tkjJhXOTnILf5zmvYfmWIDPI6elcpa3FvplulppkKtL/G6DgH64BJ/ComfUJGy74OT/n9a+ZxuN9pUvFXPFxMJ4qfNLRdDrpD0Gckc9KK5a01OaNlVwR9TkH/P9KK8941R0kmjklhJxdtxmt6pkswYshPyjrn0PvWM1zPI4yzZHoasTLJJqM6SqgjDhYsE8rtGcjHBznp2xXTwafbLZ7WVVYgHdXnUsNKvCVVvU9J1KeGhFW3MbRtTeCZUnYvEeMn+E+taOvWu1o5F4VjyeuM1k31v5cp2EAfTNdbaQi40uFZAGO0YJropU5V6Lj1i9DnxE405RrR67mfp84tY8KRswBSX14ZwUVQFB/Oq2oWdxYPuCGWIDAZRnp2PvzUEDSXbAQRsWJ7J+dP97O1OxCpwk/arXzNTQo918D1Cgn8MVfvLC3vUVZgVZfuOvUe3uPal060NnCxkYtM/UD+EenvVk98jrxXpRgowUH0OGrVbqc0GYg0GTcQLyMocYyhBq0I7PRozOw86fopI6/QdvrV/ABIGPmOTXNao7TatKrYwmEXNY1Z+zSUNGzalKeIlyzehZfWrp2Plwoo/2uTUtvrmxwt7b7B3dOcfhU+n2atHvfpj8aj1Kywu5FyO4HNJRqQXNcq9By5OUdfaX5zNe6eySI3LIvr7VVhsrtyFEDhunIOBUGmzvp94rRn9y5AdT6V1buc8udp5GaunGM1exFWpUoWjuujM+20dEO+7YO5IJRR/M96vytuPy9B0A6YoIwaTNbrRWRxSnKbvJkQ5J/i7VLuIBGS1NRRn05zjsam2gDpz0zQJtDFfJKjqOMU9lwAew7UDOOentQuOq/MewBxmnci5k+JNQOmWHngb3PCoO5rEtJ9Q1Sw+2SO42jkITgVP4pbzNVMTfcjQAD1zyat+FroW4+yOB5TjIJ7GuRy5qlnserCPssOqkVeW/wAjIhvLq2KmCaRefunkflXRaRqS3uUkXy5wM4zkNVPxBZrDN5kKqEbngcViJMYLiOaIjcrD/wDVWXM6M7dDR04YqnzJWZ2shwCyjJA45wM0DKQhpyqHHzHPH4U9XBiE5wIyu/P1rk7+4lv7guWAh3HC9MDtXXUqqKujgoUXVdtkjcuNR0uY+Xc4kGcA4psGl6RcuXgy/wDsBsVhpAAhOF2gZz2qJj5LiaF9rg9jXOq8ludiw1lanNo7RFS3hEcESRKOoH+NQ5JbjkZ7+9Q6VfLqFkJiAHX5XHXmrMmcDFdUZKSujzXFwk4y3K97bx3sa21woZDk5x93jt+JH5Vy99ol/aTERqZ4eqyKefxFdeMEYzlgM5xRuIOep9elDhGatJHRRxM6Okduxwf2e6LYW1lJz02k1o2Ph64m2tfv5EI/gHLN7e1dY0rEEbivvUTMSfmyeenpWccPBa2OiWYVJK0VYIxGsXkRII4ghRFA4HFcbcqYLhgAQyHkdBXZjPX88Vnavpa3pMtuVScAZU8BqupDnjymeErRpzalsx+n38U0SB3VZFxnPc1leJbiOeRSGBCqB0qsdJ1FXA+zOxz94YI/nVq30aO3iNzr00YjTkQhvvH0P+ArGKqJcjR0RjRpT9opX8lqV/C9g8s0128YNuylFyOH9SB6VstpVkIyn2ZAOuBx+VYd3qF3rsxt7Vfs1ogztXj5ffH8qxlaayum+zTOpj685/rURqOhF+z17m7w9SvJylLlfb8rs7mz022gYskQ3E5LOc1Hr10baxPkhcyEqGXoo5z+PGKpeH9We8ASdcTLj0x0PP8A9YVJq9pHHpMMdtHsigJCrycZ56n3NdFGt7d3X9PocSpuFdRq9zK0hFd2AeNmGGkAOSM9D+IBra2KhIcYUdWPArI0m4VMIzDjk9K2XlhKDOxh79K5cM1qpPU3xPNzmFqUaAh4wASSeB3zRTNWl3SKAQykgeuMn+VFY4iUebU7qXwLmJtUtxbT+Y4GzjJ7e2KkW/3QsC+zA6+ldBPEkoIkGSRjpVD+xLISFijY/uhiMVawk4+7F6HBHEwlFKpujJhga+uzHE25hywH8I9fauqlubOwhjgeVAFAX5jz0rOupYNKtSIYwoxnA6k/WuJluXvpxKWJHBweCP8AOazqYj6svZUtX1ZcaDxmr0ij0czwzoZY5oyo6lXHH1pQSBhWyp9K8g8UwaqBDcWRDWaLmWNJBHIZMja4JGDgDAU4GTzXqGi3pvrUeaVFzDgSYXG4diP5Vph8V7dtWs0Y4nBewgpp3X5Gn1HPcdKQDA9PalU4J6gfypce55r0FqeeVbq8+zTwRva3kqTHaJYITKqHI+/jlR79ODWJrcD2+rO+DslG4EdM966XLDkH9aju7aO7gMM+cdVYdVPrWNSk5R31NqFb2U7vbqZGn6gIl2yDA78VsRzoV3IwxjrmuZu9MuLZmSYkL/DKgzmoo7kiMKj4U8YrJVJxXK0dc8NCr70GSXuPNcD6dOK6u3ybS3J4PljOa57SbGS8lEjgi3U5Zj39hXRyYLDaPl6Yz0FbUIOMdephjJLSC6BjnODRj07UE9h+VR3Vxb2sZa6kCDsDyT+FauSirs40m3ZDyw6HrTy5CMQhcgZ2jq3tXLXPi2xiuNginZc/exW5p2q2V+AIJCspH3H4P0qI1YSdkzaphqtNc0ouxeDBgpYMnQkHt7Uq4B6Yxj6UxlOTkZxSOVjj3TMEUdS3GK1emrOe1zC8TRmLUVnI/dSgDcOxFUra4jEkZxyo7963J9Q0i7hNtPcLg8A4x+tZlzoU0S+bp7i4hIyADyP8a4pxTlzQZ6lGolBU6vuvz0uauoMmoaVLJDgvGN2Aa45kYyRrjJdgAB3rQih1EBoo4JV38MOlaukaJ9mdbi8KmVT8qg9KbpyqNOS2LpyhhIv3r9iz4if7NocMUeEyFjwOMD+lY2m2f2iJ2aULt7dOa3dat2vdLdUyZAdygmuORmTOHKnOCBx+FFeLTTJwceai1F2dy2JdoZAeBwafbQTXav5ClgvUgdKr6Zp0+oyuIhtjB+eU9vpUfifx5ofgq1+yJKJ5gfmVPmJPqauhhp1nZI6KjafJSV5fl6m/4Zt3it75ZNyZfHBx27VrsDkHsK8u0341eGJWkiuVuLUuSQ4QkZ7dK7fw74r0TxBEDpl/HK4A3R9GH4V2SwtSktYtI4sTQr8zqSj+pudR6d800gZ9D1z3px6jHTv3zSZyccc/nWdjiQbeenHpijgmq97fWlif9LuFRuoUDJqg/iXSvMRHnaIu2xCy4DNjOB+AP5VEq0Ibs1jRqTV4xbXoax69ecc0h9un0pkM0U8YkgdZIzyCpp7dCF69yaqMlJXRFmnZjSxPBP8A9asLxa37m3j4IIJ/Gt3IIBByD071leJLZrjTw6cvETn6Gq3ujowrUasWzK8PTPbXhWThJRjPeotTsTHNKWYAKRwetVI53SRHcgbflHcCtrXN01lb3C9HXae3IrzqDupU311+49Sd4VlL+bQ563mNrdxyxkA5x17V3sKK8AVlUoy4Kjp+VcCkMt7eQ21sheSTByOigdzXX3mp2OjRLHczF5woHlx8knHf0rPCu1Ry6W1M8fBzcYw1kULrRRKDNp0ySxnO3awPIJB9jzmqTaXqUmFKSKwIOQQB17+x9Ktw+K7WSRY/IeNTgLyOPQcU+913zExZgYPO5h2+lbTq4es9XqKP1qLUZR+8faaQsQ3XEiktwwBx39/pRWK9xdNKTLI7N6ZyPwFFc0q9ODsoX9SpYerJ3cztAQxGDketK2D249qaAOQBxnNKOhx2r1UeSc74lnMMkZZQyZ6ZpNPhsdRn8xYRAoHIBx+ArU1uyN9Z7Fxv7ZHeuYsru60xpImtU8zjmWM7Rz1yPavMt7Oo1UV1dtadz1KP7yjaGkl5lzU4Y4ZSsTZUjtxgelXfCCn7RcHlRs559xiqrtc6pInlwJuJ42Kenua2I4hoemTMx8yZsFiBgegXNVhqXseatJaCrz/deyfxMtX2oW+npmZzk9EXkmsiTxJLnMNqgGOrsSSPwrFZ3uJ3nmbLue5zitEWAa3DZwcdKTrVZ6rQI4WlSS9pqy/Z+JVZgLu38sE/fjPT8DW8hSRBJEweNujVyFvpckkbzCLKLzkitHwtcsty9ozEpICwyeh611UKkr8tTc58Th6fK50um50IPy4yCp6g9MVj3F5ocU+1oI5H7lFJAqt4kviZBYxHbjDSEdfpVS10iSS3M8aAqOKUq8pS9wmjh4xhz1JNX7aG7BrVjOREjtEBwuRha0MfKGzlexB4rir2JolBaLGCARnHU89fStTw5qDRzi0lbdE3CEn7p9KqlXblyS3FWwaUOembl3OtpayXEnRBnHqewrji0+pXbSTMWZuAP7vsK6PxZlNHccYDjcfQVl+HR/pK55PpUVE51OV7F4S1OjKqtyJ/DRn+cBcnpmqlxZS2XTKOnII/nXbHIY5zgGqOvRrJp5dj8wPGe9XOjGK5oipY6o5qMtUyTQrz+0rBGcjzo/kk9zXNatLNq2pyQROViiO1VzwT61oeCX/0q8RSChUGsvULebT9YkLNg7vMQ+tKcnKCfQ0oU408ROK3tp8zQ/4RN4oY38wSN1dTwPwrLstRn0vUAYGcwBsPH1HX0rfbxQv2f/j3cy7eueM1y243VyI4oyZpiSwx3JrOTjzJQNsOq1RSWJWh6O824K6Y2soYH1qLJOc5p6RCOCKNcfKoB9qwdZ1+KycQ2wEsvc54U12Oagrs8ejRlVly01c2gTkdcZrN1DRra8cuMxSE5JB61zR8U6hHKGeKNkB5UDkiup0PVoNYtzJCNsinDoe1RCtGbsdVTDV8KvadO6PP/i94tl8F+HbfTdPkAvLzcFcAZUDqf1r5y1KaW7j/AHjF3kOWcnJJ969i/aRWN73TXZSWiVgMdOTXjq6fduPNVSiAZy3FfV5fSjDDqy1Z9BltNKhzW1luR2unxrkzShcc7Ryatw60+kyLd6OHtruEjLI33gKouMAGN28zoxJqqbBkly8mcjcQDXTJyS5bHbKLStBH198MvE58W+FotQcFJ+UkX+6w/wA5rb12/wD7K08eX81zL8se7nnua81/Z1t5LfwzJgN5c0hfB/Kus8bEtrVqh+6sXAHua+WxkVSnNR2R8y8NF4z2fTcxyJZ5d0waWRznnkk1vr4blNn5siqGA3CM8kVe8O2lukInLBrk8DPVR9K2DJibDAkmvNo0lL35al4nHSUuSnpY4WxuptLuRLFkw/xpngiu4jkSaOOWIko43A+1cbrNuba9mh2ZRjkMD2xnkenbvW94ZkaTSEB5Mbsoye1TTbp1uXowxsI1KcayNQhu3Xv7Cl+QqyuAyMMMPakP3gc8elI65GTj8K7dTzDmtT0SWPM1qPOgBzhDyPqKrK93JaJaCGR9p4G05NdYpKMSpxinNKzkgk47kGsp0YyfNszujjJ2Skr2MPTrV9A026v7hQbxxtUA52DsPzribiQSzM0rEseWz/WvRddgNxokyofnQ7+favPnWIRrtfLj7wIrjx1P2dFRh1ep6OWz9pzVJfE2XLKDdCWC7mJx6GrdhIYp2RFJB+XBFV7K62WYiOMjJJAx1NS6ec3SccZycivMjZU/M3qXfNzGjPpMxjMuF2kkkD86K2PtKCDjk46UV7HsKdRKT3POhiKvYoW+oSxTbLhNqk/eHb8K2kZW5GPWuYv5fMmxx9a2NOnA0/dKy/KTj3HFFCveMnLoZ4il7qkkXp5o4kLSuqrVFfEFpG7RqzuF46cVzl3df2hdyAy5jj6g8AfXtWvZ6PlQzYzjuKyhXq1fejohvC0qcb1Xqa0Gt2c7eWZDEx7SLgfnVXxNH/xKpsrzlc9+M1ianZ/ZgwC8t/F0rW8Oym+0ya0ufnRRxjOdp6/katVHXg4P4kS6EKNq9PZNGJAiyBCWC/0rq7b7NBbhpZYSF4ZmYEKR1H1rl9Q0650yRyyu9sThZFGRj0OOlVGm81hubIHPJrKFV000lqddSisQk4y0N3V9cNxut7T5ITwznqw9AO1HhdfO1ZZQDtiUkn9Kz7LT572TbbxMVzy7DCj8a6yws49OtfIhO8n5nc/xH/CtqFOcpe0mc2IlSo03Sp7v+tTltQjV9euy/XecV02iyCTTU8s5MbFWANZHie1aKdNQjBZGG2T2PrVDStU+w3WYmBVzyufvUqM/Yy5ZFTpvEUE4dP0N/XowbYlhk57VzK5ilikGAwYYz2rprzULK8siVch+oQ9QawrCJr6/hjRSyr8xKjoM0SjesnEWFbhTfOrWOwvYBeWbwNj94gI+tcRC8trOYnxHLGcc98V3Tt+8GDjHAqnqGn22oricFZAOHXrXRVp82sdzjwuIVK8ZL3WZMeufu8SffHqetUtR1E3OcEY649Ktt4ZlEmUuVI915q/p/h+3t3Mk8hlYDhcDFZKnUlpJ6HV7XC0/fjqx3hWzNrZPO+MzcgEcgVoahp0GpQ7ZyEcdH9KlnlSKJpHISKMfkK4+5vbvVrsqjFYicIq8VvKSglE5KcKmIqOqny+Zpp4ZKI6Jdqyn2Gf0rR0nRrfTMtnzJum5hXMXtje2G13eQL/eB4HpWlo2vyGUW97yp4EmKzjOKlZrU6K1OvOm3GfMuttC/wCJL82dkURv38wwuOo965bTtN8wHcCzMc/WtXxsrre2T4zHtIB96l0eYbQTjIPUVFT35pPYug3RwylDdmXqelmCHOPxrJ0C7Ola/G4x5c58twTiu11maGWyADAtu9a423tGvNbtokBIWTcQOwFROmo1FynXhqvtaMlV2syT4v8AhOXX9MDWJzeRHeuRwcc182azfXsNzLZ3amBkOxo8Y5HFfakjqZtu324rm9b8FaFrUu+/s4pXz1K19Hgsw9jHkmro5sDmToQ9nPY+UdK02W8eOK1ie5lfkJGua67R/hVq895DJqLLChwfLBySPT24r3fT/BVppUi/2QFt1HB+UE4rVnk07SJPMuZt9yRwvU1tXzbpTR2Vc09paNFajvDWmLpGnRwIioMA7FHSs/xlYs08F8vKKmx/YZ4p/wDwlkJY4tZdvrmlh8QWl/K1uDhjwY3714NSvGTfN1POhTxFOr7aUfUxIWdWBRip9RnNbum6qSyx3Tbhj5W61Vn8PzR5eykLKTkRseR7A1UOm6kWCpbNuz+FcnJOD9065ujXW6JPENyk11I0RycBRjpW/olu1npMMUn3yN7A9s1Q0vQTG6XF++50OVjB4J962iSWYtk/hWtODlPnkceJqxcFSpu6Q3Bz2xmlbjdjoef8+lDMQOPyNMyTknjj68V0XOTcUnJ6e1GMfMWRV9ScCormZbe2knbB2DgeprmLhb7UCJ5wfKboe2PQVM58iOijQ9pq3ZHUxXlsc7LiBx0K7x0I6VyWt+G7pLnzdNja4t3G4hMFl9sdxUZ092iBG1uccUsE+p6RjyyWjySUbkY9vSuKpiHJOM43TO+jRdGXNRmr9n1KdhouqPcgfZJYk6l5V2geucnmtHUNPbRbBru4ZGVR8zryFFdDYajHfwiVSc9CpPINc18VrpoPAl+yTGFsYGOp9gPesfZUadN1Y6gsVWq1o05JLWxm2GsG+t1Nk++FuhA60VV+GOsongzTo5Y3EiqQzFOnuaKurCEJuMZm7qTi9KZtOGdjhhuzjOM1uSQSQ6TtXC5GTjPU1WtrdbaTaAHm6knsfarR1IKxjuoW2ZxkHNNwiqbpt2cjlqzlNrkWiMbTQrDLOGIHQjOR3rrbeaMwqV64zisptLgmUT2Lkd2UVQluTBKYN48wDO3ODgHGcen6VUKkqC5JImqo4l+69S7rU0TRsg5ftj+VWPC9uUgmnPG792B/OqNhpd1fOJCrRQZ5kcYz9B3rpUjS3hSGBSIl6epPrW2Hg03Ulo2YV6kadP2MXd9RVJXJHfio9kXJa2gLD1jGaf196Mdcfzro31OIeshcYPyqONo4FN6HAqOWSOLHmNgE4GAf6VMEJO3AJI9aOZXsJq2o0gMrJIoeM9VIrEm8O7txtpljyxIXnGO1bjJtbnI/CjjH6VMqUZu7NKdadP4GYEHhucspnuUWP+IL1I9q3LO3isYTHaqME/fI5P1qTnIFKOc1cYRjsFWvUq6TegnofekGcjpjFKB7/lSHjJHJqrmQZJY8809DjrkCkxjqcZ6U5QM9CAKLiZkeLJMaZGgUgSPg81l+H8R6jATnGQP8K2/Elv5+mFwOYjux6VzlhIIjG4yNpHUVxVG1WTZ6eGtLDOK8ztpyt0rwzjKt0riNStTaXUkW0jB4I/nXbNtYRzLn5gCDWD4rh2+TNxuPBPrWuIinG5zYCpyVOTo/zJYo/wC3PD4Rj/pEJwG965sPcWMnlzRsH+nBrp/CkezTpHwRuc1pXM1rHj7Vs+h60OCnFNmqxHsKkqSjeN9jio/t1+dlvCxB4yRgV0eh6WmmKZZCXuZOCfQegq7Ff2UjeXBIit78U948vkc/Srp04oivipzXJblQ4jLEjlqjZvnxg46Uy8u4bGPdOwHoo6msl/EMeci2fbVymluY06NSorxV0aeo3Rs9PnnH3kXj61wkVvJLMZpmLvIclick9/612Mk1vremSwQNtlYZ2NweKzdKubW0BivoCJF4yOcGsaz50ktjuwknRhK0fe7dbFaWxSCLeWUse1ZNxZJO4lUBZUOQwPWuze60mRSXAbj0qpcXmmmJkt7chsD5sdKxnRjo7mlLFVFvF3LGhXbXOnAux8+I7HNaBlfn5jgDtWR4aixb3En3Vd8D8K1iCc89O+a6KV3E4MRGKqySI9+Gx0/GkYkngn6HvSnrjv3o2YBz068nNWRoNB44J555PSkBJHII7HPWncjHPWo1dXGUYEDrjt9aTlZlIi1ONp9MnRM7h82B+tc/o2q/Z40WQnyxlc+vNdOuWdhjMY+UjH3j3/Cuf1jSHtnaa2QNbcYVf4Pw9KzrQcopx3R2YaUGnSqdTTW4tLyMsyHOM7lGMVXWGCXdHFcHryjjP8qwIpcKFEpVTTGnKOGjLgtjaADnOeOK5XWbXvLU6VhGrqLNi1tJrTWBFFgxuMkA9/6Vl667ahM8N1teFT8qn2ra0y2uY4prm8Rg5XKqfvAf0rIVC9zhmVVOSSTUTklTlNKydl/mVRknUcm7tLcl0SC3tLNo4YlCY/hHGaKlt4F5jL5I646Zop4efJFoU5JybbJYZm/tJiwBGeRnvV+aJJgxKDb61k+Wy6gyuQuTwOufxrR1K/S1tyka5JHy+/1qPaJUE5dNjKpFuUeTchs7gWmohV+4fvD2rbnt7C1mN7LbRGYJt8wrlsZ6D8cVxduZJrtSxJZyBj3rd8RTk3scKk7Yx0HfjFVGvJUIye92kKvQvUjFPdahd6xd3Tnym8pO23r+JqD7Vfo2VuJc9fmYmn2iLNLGE69z2rZ8q3Vtg2ZHqcVpTjUkua5M5U6XuqJV0zVsv5V65yzHbLxxz0OO1bDYBO4gADJPtXMal5MUpQYQN9361dvbiRvDcTAnc/7vPfGa2jWfs2+qMKtBScZR0uZviCVdaiNtsIs1YHHdyD1piW4jQeVJIGHUbzSwARqCPmwOorVYLcaVIxVvNiwQV9M965lFu809TrclSSjHYj0/VZreQR3BMsJ4yeq10JXjK8qwyD6iuNGCh5Htk10uiymXSoix+6SvNdlCbmrPoceMpJJTiXNox3wKUAYxTJFVpInZiGRsrhsA5GMEd6kk/dgHAz9OhrY4RO/PWlCjg8AH9agtZ5ZJXV49oDYB7EVYyoJxgD+lNhJOLsQzucKVXKc7ufu4/wA4ptlIXIzwferDDeckcjp7U1IxGcgUtR3XLYkKh1dHHyMMEHuK5LUNHmsrnMSl4G6Y7D0Nda33f5UsTkcH5h6VM6amXQxE6Lbjt2MKx1jyLcQzLuC9KilSfW7hUAIhHXPb6V0kkUL/AHok3fSpIlVV2oAvGOOKXI+o/rMYtzhGzMzU500uyWC3UByOMdB71yxR7hi82WY88nNaGoN9q1OSRmwinavNRrgPsB3HpnpmuWq3KXKtjuw8fZQ/vPVkNrYeezBByvzE9/zrb8P3LGOWCY5aIEhvalKppmmEk5mm4ANUvD5/4mUgJ++h61pFchnVn7anJvZbFKCJtWu3lkJIyQM9q1m0eLyyFAyKz9FlW3lkR+PmORnpW+twjAFWHvVpKTdwxNSpCVoaJHKyRPZXW+IlXQ/5zWjcwJrFobq3VVuUH7xP71JrLRmUMuMnr3qtoEzR6sojOQ4IbmsLqM+U3blKn7VaSX9WKLI+7EkEi44+73q3HphMYkvWWC36nd95h7CuuD4JZlHHNcwlq+s3Uks1wEKnCr2x6VUqKhqRTxTqJt+6l13J11/TraNIYopfKTADAfrV60vrS9JEEnzf3W4NYFzpEkTcjIz94Dg1mXEDwsD91h0Ydaj2s4dDRYWhVXuS1O56+g7U1gcjjr71U0K8+26arMAJIzsYYq4x5P09K6oTU43R50ouEnF9BpAIGDzVTVLuCxiEkwLTniPafm//AFVdi5cbuQPXtXHapcNc3sk2ec7VHXGKmpNQjzM6MLR9rOz2QHU9ZmZz56RKXyoiXGRgdfQk5qa28QX9ow+0bbhOhzgGuls4I4rNUdFxs+buc4rlL+MLNleh6A1yT5/Zqrc7KMqNZuDgrI3Y00jWYPP+zjJO11B2nJ7ECotTl0jwzp13qd35dnY2yeZNO+XKDIHuepHA5yaw9KuTZ6ikij5JPkf3rrpfmwWwV9CM5qqNRVbqS1Rz4inKjLlUnyvzH4+Zt2fcd8VymqWz2t42UyjHIbHUexroVkuPtewxIbbZu87f827P3duOnvUtw0c0aw3MXmREEltvCn69Qef51tUSqRcXsRQqujK+6ZzOnSbbhd+B/KitGbRrSL94Z5Y4upDEfzorg+rVo/CrnVOVOq+ZX+4juVjvlM8DFnUjK4waz9Vla4jREjlefpwh6/hUx22kqyWsqsobaSDnODg/qCK6SzmEkCyj5S3YVr7CNeNk7K+q8/IJVPYWklddDL8O6U9ni6veJdv7tD1X3PvVHUAw1OQsSScEHFdSowSe+Sc9ao6np63YUowSVehPf2rSvSbjHlWiOenib1XOp1K+iW5OZXyqjnHvTtagcRNNBLGjAY2vHlSfqCCP1qnG+o2OYzaysCeoXcD+VRTrqd44/wBEuWH+7jFVUlF00omnI3U53JWM15LiSULPAFzyHWQOAR7HBH5HrXRT2kp8MxxbSJAPNwPTNQ6fosm8SX4VEBz5YbLN9fSt0uSSTg06VB+zae7JxOIV4qGtnc5O3dZACDwfwq9BdNGssKsNsi7Wz0qTUNGLy+bp7qpPLRHufaq0Oiak8mzy1jHdi4NRyyTtY1dSjUjdyt6lKRymI0yzZwFUda7Czg+yWUMB+8Bl8+prMjGkaHIGnn8+8AxwCdv0FWbfWtPuXGJCrnu646+/5V0UYqCtfU5sTKVZLki+Xvbc0VkVWEXmKJHBYLnkgYz+WRTiwRCZOwye5+tHRRtIK4zn196QtjOW/D1rc8/chjuGMw+UYJ61YYBc4Oefpz2qKKJMkjqT3rO1HXYLVjHbr503QkdB+NS5KK1NI03Uly00aoOO/PQf/rp2eOea5keILvIZ4E2dTW7pmoQain7shZR95O9OM4y2Kq4apSXNJaFxFzj271m3ms2ts5jQmWToQvTNR+I7trW2jgibbJLkE+gqrpmkx3NszlvnHAJqJzd7RHSowUPa1dieHxHGzgSQ7V6nbzW1ZXEF3GTBIGyOh6iuPvrB7ViJEODwGHSorO6ksblJY2wB19xWKrtPlmjoqYKnUjeluWWG24mEnysCRVzSLdZnaeTAjjPXoal8RW/mrDe2wyrL82Kqm9jj04Qx8ZOWIpWtK7K5nVppx3enoQ6vdNczeYQAo4UA9qPDcm7VXOTiNTk+9V44pbxtkCFj69vzrUjFroVqqTNm4c5YDqalXlO7NKnLGn7KK1elirrFhNBdPcRITC53NgdKoLduiEK2DjFaX/CSTsuI7dWTvnrTE1DTL2RUu7fyHOPnAp1Em/dY4e1jG1WF7dv8jLil3+Y07kH862fDVk4me6kXaAuEyKux6LYoyyLmQdRzkGtFSdoC4C06dF3vIwxGLjKLjT6jlA3EE9RiuKvYpNPv5EJIUncp9Qa6y6vLa0ANxMqn06ms661HR9SxFPKQ38LEEY/GtqtpRsZ4SU6bb5W4vyKVrqxS38tjn0B5pVv7Ka2kju4QDyVccUsnh2X79ncq8R6E0W/hoBw13PvUdVXjNci9p6nU5Yb4lK3puSeFoPLtLiTnZI+U+nrWwQPXFZ95qdjpyeSGyyDCxIMms9/Er7j5doNvua3i1SjaTMJUa2Ik6ijubzsyECPnIxXFHiUqxwwY5P410+m63aXcqo2beYnhX6E+1Y/iSza0vjKB+5l+YHHAb0pVbVKb5TfCJ06jpzVmzfsnEtshODxg1zOswmC7KnLKeORVzRNSSP8Ac3DbAx4Y8D/9VP8AEBifYySAkADg5FZKXtKXL2HRjKjX5WtGYIy8kKqMZcYArslAAHPHv0Fc5otmbm4W6lO23i6MTjJrYm1KzidVDtIe4jX+tZYWD5nN7I0xd5yUIq9i4wBAzkc8GmOMKCSQBz9MVSi1OzmlCM7R7CCm4Yz+XarlwgktpQnzZUkY7j1rrupysmcbhKDSkrHMahePdTMBv8sHCqRx+FFSaZKkNxidtoyTgrnP+f60VxVXKpN62senKq6PuxjoRX11JcT5fI7cnmul0pDFYxqwYE84J6Vkabpchm826xtBBCf41vjjr0zx711Yam4Rbl1OTF1ItKnDoTenFO54xjrUQILHB6U2ZykLsMZC/wBK1nPkg5PocHLfQytW1x4JGgsCDIDh5DyB7AetZUmpaoRlruf8DUOnKss4aTkMcnPaurktYJEAKAqe4rkXtqkedM9OSpYa0eW/mZema4xkWG+BYHpJ3H19a3mTGf556ivPPFV/aaEyzzrIY5JVhJQZC5OAT7e9d7p7F9Mt2Y54I/KunDVnWhd7p2McZRjBRqQVkycDjjIHp6Vl+I9QazsxDEWE03AOeg71qk5/wrl/GKlLq0k42EFTRiZuMNOphhIKdVKRn29rJPwF3fTvUj2c0PyurD3rc0a6gS3CvtVj14zVq9vbZ4SAQSeOe1c7o2jzX1O6eKqKfKo6FbwxfPvaymYspGUJ6j2rbmIQMT0zXOaAvma4jIp2oCT34xXR3CCYkYPJrsoycoJvc4MXGKradVdmVr948FtHHbNtklzyOwrn4IcDJ6nvWh4hRo7+Ff4NnBFQxhVY7uvr2rjqScpandh0oUly9TVt4Yn0K5k25ccg1iW872c8U8R2kEA+hHpXRaQok0u5QdSTgfhXNzICrgdsjHpWk/clGSIw7TlOEu5u+K8GezmB4KZB61a0AM1u+08ZqlqwN54dtLhRuMOMnvjGKp2N81uo8tjzxxV8yjPUxVJzw/It02vxOnkjF3C0ci5B71ymr25tZWjJz3GO4q2dVmJzuPrkGq0EU2rX4QElc5Ymiq41NisPSlQblJ+6dLo2f7ItlkGcrnBofTrRmy0K/Sqer6vHYslpapvlRccdFrNkl1N083zWwOfatXKC3OaFGpJupflTOh/dWtu7QoECqTjGM4rgUmN3O1xMxZmYnr2rqtI1I3jvZ3S/viCAwH3hXL3tlLpV28cw/d7yyMOmKwxDbj7p24KHs5yhP4vzR0OmWCXMDMOMcAetZuq2iW0zo56DtzTxrEUCqLUFBgbs+tUr66ku2xHl5G4wP61zSUeWy3NaVOqqnNLRHTeF5jLpW1iSY3I/CmeJNSawgjSH/XSZ2n096taHbNY2EUbgCVvmce9c94pPmattP3UQYzXXzuFHmZxUoQq4p9tWZ1tHNdNvbc7HqTzWjNo0scJkK/KOvtWpoUKrbF9oye1X7tiljJu/i7Vz0qLqLnkzerjJKpywOZ0PUXsb1YJXY28h24P8J9R6V0Wt3TWNkzRnMr/Khz0964u/3FsROqPuBDFd2OfTNdD4sYl7PkBChPJ47VWHquPMn0Lr0IyrQl3vf5HP+X1c8uc5LVPAkrRsIkLADsM1paJpwvS00rHyUb7o43H/AAramurazBRNke0fdTtWNOjKq+ZlVsVyy5Iq7OPntJduXhdM85xj9a6DRbkapp0lrfpvaP5WJ6kdj9afc60jxMmzd15PNVPDC75byUBgOF6VooqlJcrIqylUouVRWa2K91oM0cypa3MMpkyyRyNtZgOv/wCv3p1voMxfOoTLFEDyqNyR/IfWui8ssysUBK5IOMkfQ00kh+cADuecCt3h4t3Rh9cqtWv/AJmHqN1GrfZIYyttHxhe5qrb2MkzgxowXHeotUjlt7yR2yoLeYSecA9gas2+vwpbL5qrwBllIXHvg1jXcYy5Noo7FGcaadJXuWpNMjEPHLe9UdPuJLK9WKQZik45HAPb+dC62kz7oJ0mRuPkIIX698/kKZqEJnXcqnDHse/19KJU1KHNDRoVNSd4VeozXLHyLveABC/Kt0H/AOuitTTp/tNr9nu40YrwdwyD2zRWbprEe+nZ9fUqOK9kuSpujUdlRWYkD0FY13qr7ykCgDONxzxS+ILhgCkTAEDH51T0mzmuIw8yhe3HNXUrTnPlgYUaMYw9pUHrqNznPnAAd8YrRsdQFz+5udoLfxjj25FK2kxHl2bJ5yKpXtukIBhIz2o5pwVqusWNujV92K1My9tpdNuXSRvlJyrY4Iqf+1plh8tWPTrW7p7rfWbx3CLLsOMMM5FRnRNNB3eS647ByBSVCrD3Yu6L+sw+GtHVHPRCfUpUtUhWbJzjb09z7D1rto0SGCOGM5WJQucdT3P51TtZraBvs9ukcS99owT9T3q51zggrj8h6mumhCNNPu9zkxNZ1GlayQp+pPt61V1O0jv7NreQgfxK3Ugiqdzr1pAdkWbhh129KhXxGgYeZbbV9VOaqbhNcrZMMPWTU4xMa4tLyylWKSJipPDgEg1PHaXNyVW3jdmPHQ8fWursL2C9UG3YMO6N1FXldicA457DFYRwvd6G08fOOjjqU9KsU0yBvmDzOCXbGAB7e1SSok0bRySACQEHa2Dz6Vzus6rcXU7W1kxWEHBZerevNZtxp08EavKGJPOccn3q5YiMdETHCSm+erK0mdLrmnvcWEP2bDSQfd5yWHua5mGcuSjZV17NwalsNQubCQNG5ZOMoxOCK2buzt9bthd2BC3C9Vzz64NYztUXPBm8L4ZclTWPR9vUt6IwXTbkkgdT1rmS/DsccnoPrVtYdTQND5L/ADDB9K0dJ0RzKJtQACrysY6n61bvUskSnChzTlJO5paFCYdFjjlXO/khvQ1UvfD0bEtay+Xn+HGQK2mbOAMBRwPao2dBgHv6V1ypxktTzI16im5xdrmFB4clZh51z8ncAc1Pe3sGjwm009QbjHzN6f8A160b25W3sZZhyyjge/auf0rT3uw8szEFj8zH1rFxVPSO51Qm6qc6791dPMoWgHnh58Ek5JP1rrJJY0teSNu3p6VmXOlrEnmxsSF7msuec7SN+c9s9Pw/SslN078+5tOKxLTi9iKJ9uuQNGcfvMZrtblFmbZMiuMnIYda5jw1aiW6knkG5Y+BxwTXShsK7Mw29c+laYdXTctjHHSTmlHdIzLzSdKRPMmAiUc/KcZqtFqulWJ22luzH+8AP51Qk361qB3NhAdqjtinXukTWYyq7kHdR0rObin7qubRpxsoVptvtc3LXVrS5YDf5bZ4DdKx/F9rsuYpwpMci4J7A9qyWAYEZORwa3NCvRdxPp99tcbf3Z6n6UvbKqnCWhXsPq0vbU9Ut15FHStRNqNr/MD2qbVdT+1rtUhVA/Wn3fhyVGzaTAr2D8Uy28LSNKrXVwEAH3UPb8ayXtILkRfPhXL2rlqZejWR1C/wHBijYlmHPQ9PrXReKbb7VaCWIZaDORjqCO1XraK1s4vItnjUDqCeT9amJwexX9DXRQo8qfNuzmq4uU6qqJaLY461vmisxFE+xDUM8xCsdu9iRkFsd+f8966G98P210GeF/KY8lSMqT9Kqr4YcS75rnKf7IwWxWE4VIrkWx2QxWH+JuzMVd8soijBaVjgAV0E8y6JYpawbWuWyzOecH1rQsbCy06Q+QgWRzjc55Y88D34rkp5DLNK7O7F2JJPYeg9qcKfsV7SfTYmM1ipWS91fiSJc31zdfJPLu68f/Wq9purSR3a2t+wZWOFkJ6H3pNGC29pc3oBJUbR15H/AOrmsjUJFkberKVPzAjp+FSqs+R1G+uhtyRqydPl0WnzOq1G0jvIfKlByv3Wxkr9K47W9C+UfaNYhhQDhDEPzIrrEu1j0SO5k+d2QAA9zXD66st7C4ErpI4x5nU1pVnTdNVZkYKFS7inZIpaB4VXzytnrdveSbyymRijgE5wM9h0HoK6lrTULaXyJreUOTnj5lPHUEdK5jT7Uxopk5YHBOOOlWtE8ZTWOpizvZG+zhiqu/zH2Gc9M1wrFwXu6o7q1Kq7uDUrf1/Wh2elWc9q++ZWYSYUKMfL94lmz+A4z29yCmSa4sm4rtK/wgA5x3z+NFd9GKhHTW54tSE6kuaW5W1NWNyw24y3b8K1oXSGJFYqDjGBx+VQalaEncv+8e+KyZZpUVUkkOeuRwKypT9jeD3ubqKrQST2Ne9vRt2xsCO2KzJWDEZJJPU1D5oOFBU+pPb2+tSW0Ul1IEtxuOfmI6D3qJSdR27m0aSpo1tAj/dTsQQOFrSblTt5PTj1qOKEW8KRIMqBzznNSqQVyOhNeitEo9jzKs+eTkYeo6dIbgywMwOcjFZGs3l0GWyiOGKbpD0+i5rtD0O7kVxt8VOpXO8AnecfSuPFy2S6nbgpc8veWwaRprzpucBABzxwK1JtD/dEo+WA5HrV3QSpt3VTzxVqaVomJJypHTFUsPHku2TVxNT2jUTk4TNaXIKEpIp4I/z0rrbq9Evh+e7i+95Zzx0PSub1Ek3LbsjPPBra8PbLjSby1Y88nB9CKmlUk6codisWlKMarWzX3HP2GI3jcZ/Pj6/WutimS/tgko3ADle31rjbElI9pByCQeOmD3rUS4ZIV8oEOKihVik4y2LxVHnd1uO1XSWgZmRWMR5B9Pal8JTMmqPCeFdOgHcUr6lI8JRmyD146ml8J27vcTXbIVVF2gE85P0q6No1Pc2Im5LDyVU6YnvnvTt3qajGTnn86N/PI/SvQWh5FhxJAO4kY96rXMbSKNuQD3zU4cbgKS4ljgjMkrBEX1/pQyo3T0RRvrd5dKljTlxhgPXFVdF1SBYPJlbY69Qe1TSa/Crfu4nYDoemailuNLutpurfyJH6N/8AXFZS0ldHXGEuRwqRdnroT6hqMCKY4mUkjHrXP2lnPfzgRIQmeXzworfTQbMEMXeRT0y2Qa0o0WKPbEgVPYVnKm6ruxxxEKMbUtX3ZBbQR2Nstuh5HPuabqDMdNuAoOdh6VMVLH3pQMgq4+U9vWt0uWNkcvN73M9XucTayMmGRiCO/vXQ2OtqSIr4hGPAfHFYd9aSabclHGYyThscY9KhLhlG7nuM158KjpNp7Hs1KUK6vuu502oaZBcwtPAwDfeyp4NYOmKy61B5YyQTxnGRiolvHhTbGzAHt/hWz4esWQNeXAw7jCA9QKqXLOScNzJqWHpSU3dPRG2zLErPI21Fzkk8Vz+ram1y4jt3ZYR6d6veIZ2js444yB5jfN9PT61h26CRxxkfnXRXrOGkd2YYSire1kV5EYKSvJySck1r6RdT26M1wzfZeB83P5VoQ6ZamJM8k9ayNXmQXYiZsRp8ignGTWEVOC55PQ29rHEfu0ixf63KzYsgI1/vMMk1Tl1PUYZf9cc+hAINOs7KS9STyuDH68VWvYJYJds2RipliKkldbGlOnRT5Ekb+jawl/KLe6VYrgj5SOjev0PNczcW/wBnurmORn8wE4+bjGeAB0pJgw2yQFkkQ5UjtW3qsTapp9rqNvEDKF/eqoyT7041HWi4PcUYRw87x0jLT0f/AAR0CBdCVsnLfNn/AArmb7cx5OVJ5ya011MCwW2IbA5APY1HpWnvqFwJGBFupyxPf2rOpJKlGPU1pL2PNOptcd4thcRaIlveyW0Me+R4EjB+0ABRgsegGeg5OfaqNgiSttYKxB5OPvV0uvWEl3pIhtv9fF8yBjjdxgivP9GurhLgmbIUHGPf3FZ4mk1GCa0W5WCftKLSeqOzawhhtWkCBXA6VxOq6VHPcGQpgDJBHb6V1Umob49p3biOef5Vkwubu6eOOOUFHwCwwJOM5Xvjtn60YmVLk91G2F56d3I3NOso3sk3lwNo3ENtx3PP04+lFXTJFZWKJKWYleAe4orqwq5aMOft1ODllUbkti9Yz+dEpKHHfJ6GkuLKKQHgDnPPSoNKGFkB7uABjHatLIY57V1ThCok2tzkm3Cb5TNi0uAE7sOT1H+NaKxx28O2NAo6HHFCoBtOScYGM/r9aJk3LweM1MKUYbIidSU37zKyzF5AADjOBUzzwRYEs0aN2BbkfhXN6vcsZ2t7dtqAYdh1PsKoBcY4Ocg1zPFxjK252xwfOk27HbrtlUtE6Ovsc1y2uWxhv/NUYSQZ/GoYLmS2kWSFsNkHHqK6QrBqlizFQAeCB/CfWnWiq8FOnuhRi8JPmesWYel3pt/mDbmHBrdF1BLEHLAbh3Nc1e6XcWchYAyR4+8o/nVYTMAECSMwH3QpNTHELlszeeHhW9+LLl5+9uXKnCit3wzA0dvcXJzl2Ean27/0rM0rSbm8w8yG2hP8TD5j9BXU4VY1iiXbHGMAVWFp6ubObGVko+yi79zE1PRneYz2W3n70fTn2rIaG9QkNbyDHQBc/nXZdDn+VP3tsyv5GiWDV7xZjTxs4KzVzlrHR7y6YedmCLPJfqfoK6qKKK3t1htVCxr29TSZZx8236//AFu1OJ+U5roo0Y00c9evOs/e27DVyRnp/Q0P0KkHB49Kbk5yeB6+lBG7HI4rYzsPhQZGBwOetcnqt09/flkLeWnyoMnGM9frXWE4t5R32HFcbYkFlB+9/OuevJ6RR24JK8pvdFqGxdlXCnHP4U29gkIVZBwOODiumt9jwoVHb8Ky9XljBxjLd6ylRcI3uVTxEpztYPDEztbTW7Fj5WNuTng1b1XUF0+3DspaRvuqP61Q8KbVu7tRjkBiR61k6rdG91KR/m2oSq/Stfa8tPmYewVTEyutFqTPqupOGdJAq54wMgVd0jVBcXhjut4uHQIp3HYQCTwvQHnk98e1StEsXhdi6/M4yDx61zb/AChJV4ZDuBz0IrJ1Jxac9mdEKdOvGSUbWdjupIkmUpOiuPQjIrIuND06NjvuPKz/AA7qt6jqYs9OguAAZJl+UY7461ymyW5cu2XcnJJ5q6zppcz6nNhKVRpy5uVHSWNlpKOGhkSaReBuPIrVZT8ucfhXCNEY2+ZCo46jFbOiasyyra3J3RsdqMexpUatO9krMvEYWbXOpcxc8SRb4IJVGQpIP41jLIyDdHgntu6H8q6+dFeJ4pRlG4Nczf6ZcWmTHmaI9COo9qnE03fmQsJVi4+zkOXUXVFZSwHpUerQq90sxVHWQbkJGSCeuKwLq5vy7RwWUrbuhIx3rZ0mN/sZt9SbbK3KY/5Z1iqrmuRnXKkqXvot6XeC13IRkMeRmrepXlvcwfdy69z2rCvLe6tg6umdvePoRVYPJIdqqznjjBJoVV004NC+rQnL2iY6WQYOOMnjPeuv0mNrfT7dAGVgoPI2kH3FYdjpr28ZvbpBuUqyxk9sjOffBro3YhSGABJxxzinhabc+d7I58bUjNKEdhk0FtPKxlt4C2QdxQc++afEijhFCKDn5emTTEGRjAx+VSgdQPTr/Wu1QjfmS1OFt2tcCM9QOB0zWPqWi2upzNMoFtd45lVeH/3h6+9bAxn047UwbVBbse46Y9qqUVJWexVOpKm+aDszmV8M3SY/0mBx6rn+Rq/FaW+lQq8g8yU8Agf5xW2CozyOea57XDuvRyAQPXt9K43g6ULzetuh1wr1cRLkm9Cqwa5YvIflHOOuB+H8qKt6aVeNMfKOQdw2k4Pp/X0oqHTlWfOzWdbkfKWoZ0gX5SpVONxbAz3pF1SHcfnBP+yOPzNc5rF0VTd0UcKvb61Q0xbu6bzguE7YHWnLGyVlGOhpHBxlHmkzvIbmGYHy3BJ9uaW5lMVs7cdK5pfNt9pPXrW6kwvNOZh/rAMEVtKsqtGUobo5alBU2mtUcyBvc8nk1q2emGRQxyvHBx3qhEoWT5hjaeK6S2lT7P1wQK58Ph41FeR1YmrKKXKc9e2xgc9Me3etPww5P2lM4UqD+tU9Wk8yUhTkGr/hmExwXE+OHIRfcDk1eDTjUaWxNeV8PeW5ru6xK0juERRlmYYAFYtx4mWOVls7cP23yHGfwFVvFV05lis1GEI8x/c54FO07RYWTe7bsAADHSrnVcpNQjcwpUKUaaqVuuxatPEReQfa4kCEcleorcVkeNZIXVkfnPJrmNWsFijV4wNnXcRWj4VZpLS6RshUZSv41pQrupeElZojEUafs/a09DXztU478+lMJHPNSMqkFWCnPUMM5qKTnluh7kdTW5xIcWwcjj6U5eU9DjrURwxHGSDUiDBxznP5f5xQgaElJJjxLsCtlhjO8c8e3/1qdHyDjj9aV+Q3H/66ZG2BzgHHHPNO2oboeOHwRwevrXKahbNp9wQFJiblHxx9M11JkWNGkldUjAyWNULnVtPdGhlPnRH/AGTx/wDXrOrT5ldHRhpzhL3Y3XUzLfUpEj2Kc+2apzytPJkgtyTye1aTabpd1j7NdyRs3RS3SoW0qK2mPmNLJxwMcEVy1PaP3WmdsalJNtKz9C54TilEl3MUIUqqIxOd3rj27VzqJu3FcH5j04711kOpQxIqIoRV6AVi6ukUF2bpATFISznJOGPP5U6kUopMmhUk6sm1a9rfI2dTjA0Ex/3EXpXJTZER3feOR0roJNatLjT2i3ru24qjpemyX9yksiMLdDktjr7UV1flsPDN0YSdXTUm8UfLHpqYz+67nA7VZ0SS3VDuKCQ9N1XtcsP7QtsRn9/Fynv7VyLedBJtuYpF29cgjBomuSa5kKglXocl7NHaXFul1Ft2qwIzXHagn2ac48w+UQ2FXJPsB3P09qmtNWeEnEw6AEA8Z74q1o9s+oX6yyIfs6EuWJxz+P8ASlUcJK8dyqVOWGu5v3ToZL2JLWG4lEiiRdwDrgg+hB5BrGutVuyxe0hVBjnd1NOvbgapqJ27mgj4U44JB5/UVox2qKmMDPf6V0SnJe4tWjljGFJJzV2+hiWmqXof/SUjaPOTgYNaF5DDdWontuf7wzyDTbu3UIWUVR0uYw3wVz+6kARh2+v51k6jjpJWN7RmuemrNGjo14SvkFssOx6/X6VrPxkrgVzkjG1vVCMAP51vwFWUFT82ME98elbxUZ7o5K8EnzLqPbagLu22NecnpWNNr0ccrLHblwCVBZuoqLxBc5mECMxSMYPPt1Jo0O1gniZnXLqeh96VSryNQirtm1OjCFP2lTUE8QHeFe1VUPfJzWnZ3ltqERERYMMFo24P/wCqiWxt2zmJQCByB0rn7mKTS79XiOMEENjIK/Spc6kVzSQ4wo19KaszqWXew/PGOv8An+lNmDEHY/lt/e2g989DTYJPNjEifdcbgB2pSRkcHHvW6akrrqcdmmMYEKWPzN1GD1Has/UbL7SiSEKLmNSuUyBzjI+nFaZHXIPGOvFQTGOCMmThWbAwCeTzzj19aiS012Nac3Fprc51JZrdlVuDyCCP60VtmJZUj3rhsZOO1Fc3s5x+E7HXi90chqlq0ypg5Gc9etdPoMcP2ZVQL8uAB1rNhQEurqFccZz970P/ANaorHURa3DIw/eqApfHRT7+maqFNRpqoa1uapHkRpa0ihmCjBB7UmhTZdouSHHXtxVG5uxcOQrA7euOcf4Vd0VD5kkzg7SAqkj8zWGGalVdtncmUOWjaRX1S1eKbzFB2/lVQXkiR7Qce1de6rJwwz2xVYWVtli0CZ/ShYerTdoPQyp4tctpq5zdna3OoTAIuE/idugrrYY0hhjji4RBgH196aoCoFRflGflxj8qcrYHccdK66FP2a13MK9d1vJI5fxTCPtyNIoeN1AIIyODWhpeoxhNkrc/ToO1WtVslvoCjjEgOUI7GuZk0q9guViVo3Z+F+cAvjk4B9Bzx0riVR4abUlozspOnWpKE3Zo0dY1KOaPbC5KnpnitTwxG0eltKwO6d8geqgYB/nWXpvh5pJRJqMi7BnMKEkt7E9ua6ksDgbQFAwFA4A9K6cOnJuo+phiqlOMFRp69wALHoM+wprJ8x+YbV7nsPrSrKA20Zx2PY1h+Ib1muBZoSqIQXwerEdPoK2nNQV2clGlKpPlRYk1iGKXbGnmKP4gcfkO9SQazA5/fK0a+pPT61hfIQcKcDqc01HTcFCkuR271zLFO+x6H1Sm1sdduUW6+S+6Popzn880kbdS7AKBncTisfR55YL5beb5Ypex7HHBrakJEMyr94oQMeuK61JSjzR2OCpT9nLl7nL3tzLqNw+8nyQxCIRwPf8ArViHSJHxuCIDzgnn6gVS0yUxzRlhuHQ+xrp2bLkkD5uh79q5lB1dWzurzlRtCGiOcv8ATGtF3mTcDgZHWtnQ5FvYGhmOZYuc+oqLU7uGON4wd0p9Kq+FwW1SUrjAiYnrz0qoN0p8l7pkzcqlBynutmaj2iSLll2MMjBI9f5VXNg3OMH61b1C/trBc3TkHGdq8t/ntVdNdtMf6qQ884IyK6JRUtJHND2zV4q5nT6WkREqWqGRPuj/ADxV6C/kixG6YA6BcCtK3ubW9TMRy+PunqPwqKeCJIpZJDxGpc+vSs1QjF3irMHWc/dqrUq6hrNta+SDPIJd24xoF+cc/KSQcDvxg8dazbrxPLGpZrWNo/QjJrgfJu/7Sa4kkZ2kbPzE4+la0kryRNCExJjPJ4/zxXHXxergo3PVjl9KFubVnT6Rd6JrckgFpGl1Hy8bcfiK6JAoglWPgLGcAcc44FeJW+m3mmahFf25dNkm4oWLZyec56j+XFewWVyxkjMgwsgBOfQjmrwsovW2py4/C+zacJXRjaVKFGV4PAz1zzzxW+sysgIOa5TUg+mak0ByFJLJjpg1b+0Oo4yc8kH0ojVUJSuVWoKpacepp3cyeUQW5PfFZMQ36hAqnkuP51zmt3N4hLRyYPpjqKTwvcajLefapExFH90En5j0yPasK1dyaSR0xwvs6bdzttfgkWSKWMEgk78YA9iTV3RnMtuFYc99x9P1rmtc1S6XTXJjYkA5J64qj4T8VKN6SqylTnOefxFdsJqMmmjhlQnKlbqjR1MsL6YHO7ec81LoLvHfKqq20jawUZOKyPE/iGytryKeV9sF3IqJIVyA5/hPpnsT6ir2gahbS3iyLInoMtgH/wCv6Vx1qn71tHa4SeHvbodWj72DR4KZ4YdKwfEM4ku0jyM9OOw/zmtPUdTS3iP2cJJKTt+9gKCeTn/PSsjSozNcCWUkqgwS/f3rvrz5KbT3ZxYaHJerJaI37OPNpEpHygDAI9KnPDc4PFCcJgdh+lD7QSSpOQAPU/SqpR5YKJxN3Yx+nH88VTup8Ky52qQcn2qK9v44kKxqSf7qj9MetY0l67yFlUEEEjI9O3rSnaPxM66OHlLU3o87WG4A+uKKyrTVeQrjaenB4orN1af8xUqM4vYruomWVJQHUPtwecj3rlfEzFWEn8SZI9jjFFFcVCTcGmz0sP8AEa/hwC4VDL8xrs7VQAVXgcAY42gjtRRTy37Ry5h8diSVikJYdQpb6kClyQo5PWiivRPOIpH4ZSFI3YOR1pySHyyTjO0n9KKKFuPoPckRk+nTNRvt83zTGjSoCquVyVB6gHtnA/KiimxIqa1fy2FvA8IQl50iO4Z4Y8n61aS5c308BClEgSUHHOWZgfw+UUUUm3cbS5SwWO1Bnq+D+VchqDMdXuSWJ3SH8KKK5cT0OvAL3n6GrpFpFcNiUEqVztBwOv8A9etOxiitrFJIo03+WGyRkmiis6STnqZYqTu1ft+pz015K+r28zEFvNTjHAywH9a6uU7Z2VeB1/WiiuyGiaQ8UknBLscrfKINXu44wAg+YA84ya1p7uUWaY25YcnHNFFRQ+E2qq6hfy/I5y4ncOzjAIUt09K6TQlW10ua6iH75t2STx7cUUVz09aiuXjP4S+RglzcM0kvzOed3402Mkc55OP1oorKs26judK2aJo5XjmDIcMvIIrpNVmZ/Css5xvki+biiiu3CtuDucOJS56fqjlvD0CzX8O/OxVI2YG059eP5Vl67ELS+mjiZ9gYEAnp7frRRXDS2Z3v+M15fqNt5jPmB1UIFj6Dk7iQf5V6HdxrEIygwQoGfwooq8J8TOXH/FD5/oVdUtkudMklkz5kC7lYYz+PtxXMRTPnr1PNFFFf4h4PWm/UW1tI9QuhbzlxG2c7Gwfzro5SLKKOKBFCquOR1wKKKeDSdZX7CxbfNFdCpNObq2Mc0cZDZyQMHpXOabptr/aT/uxw2PrRRXozVqtjOGkXYuX/AIasr21NnLLdLDHIJv3cxUtjOFYjqvJ4NcHBbCw1C6ht5ZgkTfKC36UUV52JX735Ho4Jtpo3NGuZ55IVmmd94BbOOelem6ZbxrGsagqOuQcHjnH0oorPDvmrK5y5roo2HJgBmUBSeTgY9KqajI7W91EWIGNm4cHBzk/WiivVhuebT1kvkcrpzm5treSQDJUcD2GP6VoiFd6def05ooryKknzbnr1NGVrxAsaMvBLYP60UUVnNs0hsf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear showing multiple stomatocytes characterized by a mouth-shaped area of central pallor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9015=[""].join("\n");
var outline_f8_51_9015=null;
var title_f8_51_9016="Oxycodone and acetaminophen: Drug information";
var content_f8_51_9016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxycodone and acetaminophen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/21/26965?source=see_link\">",
"    see \"Oxycodone and acetaminophen: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/7/3191?source=see_link\">",
"    see \"Oxycodone and acetaminophen: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13135510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Endocet&reg;;",
"     </li>",
"     <li>",
"      Magnacet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;;",
"     </li>",
"     <li>",
"      Primlev&trade;;",
"     </li>",
"     <li>",
"      Roxicet&trade;;",
"     </li>",
"     <li>",
"      Roxicet&trade; 5/500;",
"     </li>",
"     <li>",
"      Tylox&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Endocet&reg;;",
"     </li>",
"     <li>",
"      Novo-Oxycodone Acet;",
"     </li>",
"     <li>",
"      Oxycocet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;-Demi;",
"     </li>",
"     <li>",
"      PMS-Oxycodone-Acetaminophen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose is based on the",
"     <b>",
"      oxycodone",
"     </b>",
"     content; however, the maximum daily dose is based on the",
"     <b>",
"      acetaminophen",
"     </b>",
"     content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Management of pain:",
"     </b>",
"     Doses should be given every 4-6 hours as needed and titrated to appropriate analgesic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Maximum daily dose, based on acetaminophen content:",
"     </i>",
"     Oral: 4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate pain: Oral: Initial dose,",
"     <b>",
"      based on oxycodone content:",
"     </b>",
"     2.5-5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe pain: Oral: Initial dose,",
"     <b>",
"      based on oxycodone content:",
"     </b>",
"     10-30 mg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/7/3191?source=see_link\">",
"      see \"Oxycodone and acetaminophen: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose is based on the",
"     <b>",
"      oxycodone",
"     </b>",
"     content; however, the maximum daily dose is based on the",
"     <b>",
"      acetaminophen",
"     </b>",
"     content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Management of pain:",
"     </b>",
"     Doses should be given every 4-6 hours as needed and titrated to appropriate analgesic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mild-to-moderate pain:",
"     </i>",
"     Oral: Initial dose,",
"     <b>",
"      based on oxycodone content:",
"     </b>",
"     0.05-0.1 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe pain:",
"     </i>",
"     Oral: Initial dose,",
"     <b>",
"      based on oxycodone content:",
"     </b>",
"     0.3 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Maximum dose, based on acetaminophen content",
"     </b>",
"     : Oral: Children &lt;45 kg: 90 mg/kg/day; children &gt;45 kg: 4 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate analgesic effects: Oral: Initial dose,",
"     <b>",
"      based on oxycodone content:",
"     </b>",
"     2.5-5 mg every 6 hours. Do not exceed 4 g/day of acetaminophen.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F204985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be reduced in patients with severe liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Roxicet&trade; 5/500: Oxycodone hydrochloride 5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5/500: Oxycodone hydrochloride 5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylox&reg;: 5/500: Oxycodone hydrochloride 5 mg and acetaminophen 500 mg [contains sodium benzoate and sodium metabisulfite] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Roxicet&trade;: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg per 5 mL (5 mL, 500 mL) [contains ethanol &lt;0.5%; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5/325: Oxycodone hydrochloride 2.5 mg and acetaminophen 325 mg; 5/325: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg; 7.5/325: Oxycodone hydrochloride 7.5 mg and acetaminophen 325 mg; 7.5/500: Oxycodone hydrochloride 7.5 mg and acetaminophen 500 mg; 10/325: Oxycodone hydrochloride 10 mg and acetaminophen 325 mg; 10/650: Oxycodone hydrochloride 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 5/325 [scored]: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 7.5/325: Oxycodone hydrochloride 7.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 7.5/500: Oxycodone hydrochloride 7.5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 10/325: Oxycodone hydrochloride 10 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocet&reg; 10/650: Oxycodone hydrochloride 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magnacet&reg; 5/400: Oxycodone hydrochloride 5 mg and acetaminophen 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magnacet&reg; 10/400: Oxycodone hydrochloride 10 mg and acetaminophen 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 2.5/325: Oxycodone hydrochloride 2.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 5/325 [scored]: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 7.5/325: Oxycodone hydrochloride 7.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 7.5/500: Oxycodone hydrochloride 7.5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 10/325: Oxycodone hydrochloride 10 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Percocet&reg; 10/650: Oxycodone hydrochloride 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primlev&trade; 5/300: Oxycodone hydrochloride 5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primlev&trade; 7.5/300: Oxycodone hydrochloride 7.5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primlev&trade; 10/300: Oxycodone hydrochloride 10 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Roxicet&trade; [scored]: Oxycodone hydrochloride 5 mg and acetaminophen 325 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes caplet and solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F204999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate-to-severe pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Endocet&reg; may be confused with Indocid&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Percocet&reg; may be confused with Fioricet&reg;, Percodan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Roxicet&trade; may be confused with Roxanol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylox&reg; may be confused with Trimox, Tylenol&reg;, Xanax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined (also see individual agents): Allergic reaction, constipation, dizziness, dysphoria, euphoria, lightheadedness, nausea, pruritus, respiratory depression, sedation, skin rash, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxycodone, acetaminophen, or any component of the formulation; severe respiratory depression (in absence of resuscitative equipment or ventilatory support); pregnancy (prolonged periods or high doses at term)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.  Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use oxycodone with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with toxic psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use oxycodone with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some preparations contain sulfites which may cause allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of OxyCODONE. Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F204978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day. Ethanol may also increase CNS depression; monitor for increased effects with co-administration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of opioids during pregnancy may produce physical dependence in the neonate; respiratory depression may occur in the newborn if opioids are used prior to delivery (especially high doses).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F204974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oxycodone: Excreted in breast milk. If occasional doses are used during breast-feeding, monitor infant for sedation, GI effects, and changes in feeding pattern.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acetaminophen: May be taken while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Oxycodone-Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $49.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Roxicet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg/5 mL (5 mL): $1.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Endocet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (100): $51.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-325 mg (100): $136.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-500 mg (100): $145.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-325 mg (100): $177.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-650 mg (100): $145.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Magnacet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-400 mg (100): $716.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-400 mg (100): $716.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-400 mg (100): $716.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oxycodone-Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-325 mg (100): $204.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (100): $51.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-325 mg (100): $135.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-500 mg (100): $106.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-325 mg (100): $177.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-650 mg (100): $145.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Percocet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-325 mg (100): $397.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (100): $147.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-325 mg (100): $601.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-500 mg (100): $642.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-325 mg (100): $786.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-650 mg (100): $839.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Primlev Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-300 mg (30): $208.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-300 mg (30): $208.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-300 mg (30): $208.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Roxicet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (100): $31.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xolox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-500 mg (100): $297.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F204963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for pain relief, respiratory and mental status, blood pressure, constipation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Percocet-5 (IL);",
"     </li>",
"     <li>",
"      Tylenol Oxy (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oxycodone, as with other narcotic (opiate) analgesics, blocks pain perception in the cerebral cortex by binding to specific receptor molecules (opiate receptors) within the neuronal membranes of synapses. This binding results in a decreased synaptic chemical transmission throughout the CNS thus inhibiting the flow of pain sensations into the higher centers. Mu and kappa are the two subtypes of the opiate receptor to which oxycodone binds to cause analgesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acetaminophen inhibits the synthesis of prostaglandins in the CNS and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Pain Society,",
"      <i>",
"       Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain",
"      </i>",
"      , 4th ed, Skokie, IL: American Pain Society, 1999.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper SA, Precheur H, Rauch D, et al, &ldquo;Evaluation of Oxycodone and Acetaminophen in Treatment of Postoperative Pain,&rdquo;",
"      <i>",
"       Oral Surg Oral Med Oral Pathol",
"      </i>",
"      , 1980, 50(6):496-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/7005804/pubmed\" id=\"7005804\" target=\"_blank\">",
"        7005804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, &ldquo;New Approaches to Preventing and Treating Postoperative Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):26-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/1619142/pubmed\" id=\"1619142\" target=\"_blank\">",
"        1619142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gobetti JP, &ldquo;Controlling Dental Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):47-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/1619145/pubmed\" id=\"1619145\" target=\"_blank\">",
"        1619145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(5):385-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/7614777/pubmed\" id=\"7614777\" target=\"_blank\">",
"        7614777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinatra RS and Harrison DM, &ldquo;Oxymorphone in Patient-Controlled Analgesia,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1989, 8(8):541, 544.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/2475287/pubmed\" id=\"2475287\" target=\"_blank\">",
"        2475287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;The Management of Chronic Pain in Older Persons. AGS Panel on Chronic Pain in Older Persons, American Geriatric Society,&rdquo;",
"      <i>",
"       Geriatrics",
"      </i>",
"      , 1998, 53(Suppl 3):8-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/9826952/pubmed\" id=\"9826952\" target=\"_blank\">",
"        9826952",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/51/9016/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9730 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9016=[""].join("\n");
var outline_f8_51_9016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135510\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204980\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204981\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204997\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204983\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204991\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204984\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204985\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204966\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204949\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204999\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204968\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205004\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204995\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204971\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204953\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204992\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204958\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204978\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204960\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204973\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204987\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204974\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989444\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204963\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038714\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204952\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204970\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9730\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9730|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/21/26965?source=related_link\">",
"      Oxycodone and acetaminophen: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/7/3191?source=related_link\">",
"      Oxycodone and acetaminophen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_51_9017="VF congr inf quadrantanopia";
var content_f8_51_9017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Visual fields: Congruous inferior quadrantanopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 439px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Humphrey visual field showing a left congruous inferior quadrantic homonymous scotoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9017=[""].join("\n");
var outline_f8_51_9017=null;
var title_f8_51_9018="Medical therapy versus revascularization in the management of stable angina pectoris";
var content_f8_51_9018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical therapy versus revascularization in the management of stable angina pectoris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/51/9018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/51/9018/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/51/9018/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/51/9018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/51/9018/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/51/9018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/51/9018/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/51/9018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated coronary heart disease (CHD), also referred to as ischemic heart disease, generally results in progressive angina, myocardial infarction (MI), left ventricular dysfunction, and ultimately death [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/1\">",
"     1",
"    </a>",
"    ]. Although some patients with CHD remain asymptomatic or have only chronic stable exertional angina, these patients are at increased risk for sudden cardiac death.",
"   </p>",
"   <p>",
"    The goals of therapy in patients with stable angina are to alleviate symptoms, delay or prevent the progression of coronary disease, and prevent adverse outcomes such as death or myocardial infarction. This is usually accomplished with medical therapy, with revascularization being performed in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Revascularization can be accomplished with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Interventional therapy ameliorates symptoms but generally does not improve mortality.",
"   </p>",
"   <p>",
"    There are two main indications for revascularization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with unacceptable angina",
"     </li>",
"     <li>",
"      Patients deemed likely to have a survival benefit from revascularization, based upon the location and severity of the lesion, the number of diseased vessels, and the presence of left ventricular dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of medical versus interventional therapy in patients with stable angina will be reviewed here. The choice between PCI and CABG when intervention is required is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AGGRESSIVE RISK FACTOR REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even among patients who undergo interventional therapy, progression of native coronary disease is an important determinant of clinical outcome with time. This was illustrated in an analysis from the BARI trial, which compared PCI and CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/2\">",
"     2",
"    </a>",
"    ]. At five years, progression of disease in previously untreated vessels accounted for two-thirds of the increase in myocardium at risk, regardless of which procedure had originally been performed.",
"   </p>",
"   <p>",
"    This observation demonstrates the importance of aggressive risk factor reduction in all patients with CHD, including those with stable angina pectoris. This includes low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , reaching treatment goals for hypertension and serum lipids, avoidance of smoking, and, in diabetic patients, controlling the serum glucose. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal medical therapy was not used in any of the trials prior to COURAGE [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'COURAGE and FAME II trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CABG VERSUS MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CABG provides more symptomatic relief and improved survival when compared to medical management in",
"    <strong>",
"     selected",
"    </strong>",
"    patients with stable angina. The following discussion will review data related to conventional CABG; the efficacy of minimally invasive CABG is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link&amp;anchor=H4#H4\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Off-pump CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relief of angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 95 percent of patients have an improvement in or complete relief of angina immediately after CABG. The Coronary Artery Surgery Study (CASS) performed in the late 1970s and early 1980s showed that more patients remained symptom-free after CABG compared to medical therapy at one year (66 versus 30 percent) and five years (63 versus 38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/4\">",
"     4",
"    </a>",
"    ]. By 10 years, this difference had disappeared (47 versus 42 percent). This was due both to recurrence of symptoms by 10 years after CABG and to the performance of surgery in a significant proportion of the medically treated patients at a later date.",
"   </p>",
"   <p>",
"    The long-term success of CABG is limited by two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression of atherosclerosis in other vessels",
"     </li>",
"     <li>",
"      The development of bypass graft disease (ie, stenosis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link\">",
"       \"Prevention, presentation, and management of saphenous vein graft stenosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reoperation rate for recurrent symptoms was 6 to 8 percent per year in CASS, and the mortality rate within the first five years after bypass surgery was approximately 1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/4\">",
"     4",
"    </a>",
"    ]. In older studies with saphenous vein grafts, survival at 10 years was approximately 80 percent, and 50 percent had recurrent angina; only 15 percent were angina-free at 15 years (",
"    <a class=\"graphic graphic_figure graphicRef53660 \" href=\"UTD.htm?18/39/19069\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/5\">",
"     5",
"    </a>",
"    ]. However, both graft patency and patient survival are significantly higher with internal mammary artery grafts (",
"    <a class=\"graphic graphic_figure graphicRef72584 graphicRef69211 \" href=\"UTD.htm?32/16/33038\">",
"     figure 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effects on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;CABG offered no significant overall mortality benefits compared to medical therapy alone in trials from the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. However, survival was improved in selected patients with severe CAD who were at high risk because a large amount of myocardium was supplied by the diseased vessel or because of significant underlying left ventricular dysfunction. These included patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left main coronary artery stenosis or left main equivalent disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link\">",
"       \"Management of left main coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Three vessel disease, particularly with a reduced left ventricular ejection fraction (LVEF, usually &lt;40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/10-14\">",
"       10-14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H3#H3\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'CABG versus PCI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Two vessel disease when there was more than a 75 percent stenosis in the left anterior descending (LAD) artery",
"      <strong>",
"       proximal",
"      </strong>",
"      to the first major septal artery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/10,15\">",
"       10,15",
"      </a>",
"      ]. Patients with proximal LAD disease have a worse prognosis than those with more distal stenoses within the LAD, and the presence of proximal LAD plus concurrent right coronary disease is associated with a prognosis similar to that of left main disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/16\">",
"       16",
"      </a>",
"      ]. Prognosis is also worse when either the LVEF &lt;50 percent or ischemia is present on noninvasive testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=see_link\">",
"       \"Management of significant proximal left anterior descending coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these three categories of patients, the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on CABG concluded that patients with stable angina and the following criteria also benefit from revascularization with CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One or two vessel disease without significant proximal LAD disease, but with a large area of viable myocardium demonstrated on noninvasive imaging and with high risk criteria on stress testing. Patients with a moderate area of viable myocardium have possible benefit.",
"     </li>",
"     <li>",
"      Significant proximal (single vessel) LAD disease.",
"     </li>",
"     <li>",
"      Disabling angina while on maximal medical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the exception of left main disease, the survival benefit from CABG compared to medical therapy tends to disappear with prolonged follow-up in these groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. A limitation to these observations is that currently recommended aggressive risk factor reduction was not performed. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Aggressive risk factor reduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Severity of angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of angina influences the outcome of medical therapy even among patients with similar angiographic findings. Nonrandomized data from the CASS registry found that five-year survival was lower in medically compared to surgically treated patients with both class III or IV angina (Canadian Cardiovascular Society classification) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and three vessel disease whether they had normal left ventricular function (74 versus &ge;92 percent) or reduced left ventricular function (52 versus 82 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Strongly positive stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients able to undergo exercise stress, the duration of exercise and the ST segment response during exercise testing have been used by the CASS registry and investigators at Duke to stratify medically treated patients into those with an annual mortality of 5 percent per year and those with an annual mortality of 1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Low-risk patients according to the Duke treadmill score for exercise testing are likely to have either no coronary stenosis &ge;75 percent or single vessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/21\">",
"     21",
"    </a>",
"    ]. Although 9 percent of low-risk patients in one report had three vessel or left main disease, five-year mortality for all patients in the low-risk group was only 3 percent (0.6 percent per year). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radionuclide myocardial perfusion imaging (rMPI) can also be used to determine which patients with stable angina are more likely to have a survival benefit from revascularization as opposed to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link&amp;anchor=H12#H12\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Prognosis of CHD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential predictive value of rMPI was illustrated in a retrospective evaluation of more than 10,000 consecutive patients without prior MI or revascularization who underwent exercise or adenosine rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/23\">",
"     23",
"    </a>",
"    ]. Of these, 671 underwent revascularization within 60 days after rMPI; the remainder was treated medically. At two years, mortality was significantly lower with revascularization in patients with inducible ischemia of &gt;10 percent of total myocardium (2.6 versus 5.4 percent). In contrast, mortality was significantly lower with medical therapy in patients with inducible ischemia of &le;10 percent of total myocardium (0.9 versus 3.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy for patients with multivessel coronary disease and left ventricular dysfunction has not been formally addressed in the large randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/10\">",
"     10",
"    </a>",
"    ] and a left ventricular ejection fraction (LVEF) less than 30 percent was an exclusion criterion in the COURAGE trial described below [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, reduced left ventricular systolic function is one of the most important determinants of prognosis in medically treated patients with stable angina and may be an indication for revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/11,13,14,17\">",
"     11,13,14,17",
"    </a>",
"    ]. The following observations from the CASS registry are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients treated with medical therapy only, single vessel disease with poor left ventricular function and three vessel coronary disease with good left ventricular function had a similar prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with an LVEF between 35 and 49 percent, survival at seven years in patients with three vessel disease was associated with a significant improvement with CABG (88 versus 65 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/13\">",
"       13",
"      </a>",
"      ]. No benefit from CABG could be identified in patients with one or two vessel disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are limited data on patients with lower ejection fractions. One study analyzed the outcome of 135 consecutive patients with an LVEF below 30 percent (mean 24 percent) who underwent CABG; most had multivessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/25\">",
"     25",
"    </a>",
"    ]. The in-hospital mortality rate was 5.2 percent. The LVEF improved from 24 percent preoperatively to 34 percent postoperatively, and the three year survival rate was 81 percent.",
"   </p>",
"   <p>",
"    As demonstrated in the latter study, left ventricular dysfunction may be partially reversible in patients with coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/25\">",
"     25",
"    </a>",
"    ]. This may reflect hibernating myocardium, which refers to an ischemia-induced impairment in cardiac contractility that can be reversed over several days or weeks after revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CABG may improve survival in patients with left ventricular dysfunction and hibernating myocardium, a benefit that is not expected in those with irreversibly scarred myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/26\">",
"     26",
"    </a>",
"    ]. This finding suggests that myocardial viability should be adequately assessed prior to recommending CABG in patients with moderate to severe left ventricular dysfunction in whom there are significant stenoses in arteries supplying markedly hypokinetic or akinetic myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1041701551\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the following recommendations to prefer CABG to medical therapy in stable patients made in the 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/27\">",
"     27",
"    </a>",
"    ]. A strong preference for CABG as opposed to medical therapy was made for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unprotected left main coronary artery stenosis (&ge;50 percent diameter stenosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link\">",
"       \"Management of left main coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Significant (&ge;70 percent stenosis) three vessel disease with or without proximal LAD disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/10-14\">",
"       10-14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=see_link&amp;anchor=H20#H20\">",
"       \"Management of significant proximal left anterior descending coronary artery disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Two vessel disease with proximal the left anterior descending (LAD) artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/10,15\">",
"       10,15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Summary and recommendations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with one or more significant coronary artery stenoses amenable to revascularization and disabling angina while on maximal medical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A weak recommendation for CABG was made for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two vessel disease without significant proximal LAD disease, but with extensive ischemia.",
"     </li>",
"     <li>",
"      Significant proximal LAD disease and evidence of extensive ischemia if a left internal mammary artery bypass graft can be placed.",
"     </li>",
"     <li>",
"      Mild to moderate left ventricular systolic dysfunction (ejection fraction 35 to 50 percent) and significant multivessel CAD or proximal LAD stenosis when viable myocardium is present in the region of intended revascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendations above are generally consistent with those made in the 2011 Guidelines on myocardial revascularization issued by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PCI VERSUS MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with stable angina pectoris who do not meet criteria for revascularization (criteria including left main or severe three vessel coronary artery disease with a reduction in left ventricular ejection fraction and a large area of potentially ischemic myocardium), the best available evidence, discussed below, does not support the routine use of PCI as an initial strategy in preference to optimal medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H19#H19\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple trials have compared medical therapy to PCI in patients with stable angina. However, the ability of these trials to inform decision making is limited by the absence of stent (and in particular drug-eluting stent) use in many trials and the less than optimal use of currently recommended medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/29-38\">",
"     29-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     COURAGE and FAME II trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The COURAGE and FAME II trials are more contemporary in their design than the trials referenced above. In COURAGE, 2287 patients with stable CHD were randomly assigned to either aggressive medical therapy alone or aggressive medical therapy plus PCI with bare-metal stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients were required to have both objective evidence of ischemia and significant disease in a least coronary artery; 87 percent were symptomatic and 58 percent had Canadian Cardiovascular Society [CCS] class II or III angina (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Exclusion criteria included CCS class IV angina, &ge;50 percent left main disease, a markedly positive treadmill test (significant ST segment depressions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a hypotensive response during stage I of the Bruce protocol), an LVEF less than 30 percent, and coronary lesions deemed unsuitable for PCI.",
"   </p>",
"   <p>",
"    All patients received optimal, tolerable antiischemic therapy with beta blockers, calcium channel blockers, and nitrates, as well as antiplatelet therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and aggressive lipid-lowering therapy, including administration of a statin (attained median LDL-cholesterol was 72",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.87",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    at five years). Exercise was recommended to achieve further improvements in the lipid profile when necessary.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     Lisinopril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    were used as standard secondary prevention, although the specific efficacy of angiotensin inhibition remains unproven in the absence of a low LVEF or a prior MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H18#H18\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'ACE inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H3#H3\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Importance of attained blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations were made at a median follow-up of 4.6 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference between the two treatment strategies for the primary endpoint of death from any cause and non-fatal MI (approximately 19 percent in both groups). This outcome remained unchanged when periprocedural MIs (most defined as CK-MB or troponin elevations) were excluded.",
"     </li>",
"     <li>",
"      There was no significant difference in the rates of hospitalization for ACS (approximately 12 percent in both groups).",
"     </li>",
"     <li>",
"      Patients in the PCI group underwent significantly fewer subsequent revascularization procedures (21 versus 33 percent, hazard ratio 0.60, 95% CI 0.51-71).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issue of whether patients who receive PCI plus optimal medical therapy have a better quality of life in general, and less angina in particular, than those who receive optimal medical therapy was addressed in a separate report from COURAGE [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/39\">",
"     39",
"    </a>",
"    ]. Validated health surveys (Seattle Angina Questionnaire and RAND-36) were administered to patients at baseline, at 1, 3, 6, and 12 months, and then yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At baseline, 22 percent of patients were free of angina. At three months, significantly more patients who received PCI were free of angina (53 versus 42 percent); however, there was no significant difference at 36 months (59 versus 56 percent).",
"     </li>",
"     <li>",
"      Patients in both groups showed significant improvements from baseline values in various measures of quality of life. The percent of patients with clinically significant improvement in parameters such as physical limitation, angina stability, angina frequency, and overall quality of life was significantly higher in the PCI group by six months but not at 36 months.",
"     </li>",
"     <li>",
"      The greatest benefit with PCI for most measures of quality of life occurred in the subgroup of patients with more severe angina at baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients similar to those enrolled in COURAGE, PCI with bare-metal stents plus optimal medical therapy and initial, optimal medical therapy with revascularization as necessary lead to similar outcomes.",
"   </p>",
"   <p>",
"    While we agree with the broad conclusions of COURAGE, it is possible that the subset of stable patients with moderate to severe ischemia might benefit from revascularization as opposed to medical therapy. This hypothesis was supported by the nuclear substudy of COURAGE, which found that patients who had a significant reduction of ischemia (comparing pre- and post-myocardial perfusion studies) with PCI plus optimal medical therapy has a lower unadjusted risk for death or MI and that this was particularly true for patients with moderate to severe baseline ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/40\">",
"     40",
"    </a>",
"    ]. Additional support for the concept came from the FAME trial, in which a strategy of selective stenting of lesions with a fractional flow reserve (FFR) of &le;0.80 led to better outcomes than strategies of stenting all lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\", section on 'Multivessel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The observations in the nuclear substudy of COURAGE and in FAME provided the basis for the FAME II trial. In FAME II, patients with stable coronary artery disease who were being considered for PCI underwent diagnostic coronary angiography and subsequent evaluation of all stenoses that were thought to be angiographically significant with fractional flow reserve (FFR) measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients with at least one stenosis in a major coronary artery with an FFR of 0.80 or less were randomly assigned to FFR-guided PCI (all stenoses with FFR &le;0.80 were treated with a drug-eluting stent) plus best medical therapy or best medical therapy alone. Optimal medical therapy included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blocker alone, or in combination with a calcium-channel blocker or a long-acting nitrate, an angiotensin-converting-enzyme inhibitor or an angiotensin II receptor blocker, and a statin. The primary end point was a composite of death, MI, or unplanned hospitalization leading to urgent revascularization at 24 months. The study was stopped early (after randomization of 888 of the projected 1632 patients) by the data and safety monitoring board.",
"   </p>",
"   <p>",
"    After a mean duration of follow-up of 213 days, the primary end point occurred less often in patients who underwent PCI (4.3 versus 12.7 percent; hazard ratio [HR] 0.32, 95% CI 0.19-0.53). This difference was driven mainly by a lower rate of urgent revascularization in the PCI group (1.6 versus 11.1 percent; HR 0.13, 95% CI 0.04-0.43). Among those who underwent urgent revascularization, about 79 percent had unstable angina (enzyme negative acute coronary syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important limitations of FAME II include the absence of noninvasive documentation of ischemia prior to diagnostic coronary angiography, the possibility (in the absence of blinding) that the threshold for referring patients for PCI was lower in the medical therapy group, and the fact that it was stopped early [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/42\">",
"     42",
"    </a>",
"    ]. Despite these limitations, we believe FAME II supports the use of PCI in patients with documented ischemia involving at least a moderate myocardial territory. We prefer to limit the use of FFR in this setting to intermediate lesions (50 to 70 percent diameter stenosis by visual estimate) or cases where the documentation of at least moderate ischemia is equivocal.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple meta-analyses have evaluated trials comparing optimal medical therapy to PCI. However, limitations of the individual trials (see",
"    <a class=\"local\" href=\"#H12\">",
"     'PCI versus medical therapy'",
"    </a>",
"    above) become important limitations of the meta-analyses.",
"   </p>",
"   <p>",
"    A 2012 meta-analysis evaluated outcomes in over 7000 patients from eight randomized trials who had either stable angina or who were stable post-MI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/43\">",
"     43",
"    </a>",
"    ]. These trials compared PCI (with stenting in at least 50 percent of patients) to optimal medical therapy. After a mean follow-up of 4.3 years, there was no significant difference in the rates of death (8.9 versus 9.1 percent, respectively), non-fatal MI (8.9 versus 8.1), unplanned revascularization (21 versus 34 percent), or persistent angina (29 versus 33 percent). This study did not distinguish between periprocedural and spontaneous MI. This issue is important, as the evidence is strong that outcomes are worse after spontaneous compared to periprocedural MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39737?source=see_link&amp;anchor=H88286209#H88286209\">",
"     \"Periprocedural myocardial infarction following percutaneous coronary intervention\", section on 'Prognosis summary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A larger 2013 meta-analysis, in which there was significant overlap with the 2012 study, evaluated outcomes in over 8000 individuals enrolled in 12 trials (mean follow-up of five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/44\">",
"     44",
"    </a>",
"    ]. PCI compared to optimal medical therapy was associated with a lower incident rate ratio (IRR) for spontaneous, non-procedural MI (IRR 0.76, 95% CI 0.58-0.99) at the risk of a higher IRR for procedural MI (IRR 4.11, 95% CI 2.53-6.88), and no difference in all MI. There were trends toward lower all-cause and cardiovascular mortality with PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17364273\">",
"    <span class=\"h2\">",
"     Compliance with appropriateness criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for the appropriate use of coronary revascularization (including PCI) were published in 2009 jointly by multiple United States (US) professional organizations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. These criteria take into account the following patient characteristics: clinical presentation (stable or unstable disease); symptom severity; ischemia severity, as determined by noninvasive testing; presence of high-risk features (eg, left ventricular dysfunction, ventricular arrhythmias); intensity of anti-ischemic medical therapy; and severity of disease on coronary angiography.",
"   </p>",
"   <p>",
"    The extent to which patients are being managed according to these criteria was evaluated in a study of over 500,000 patients enrolled in the US National Cardiovascular Data Registry (NCDR) in 2009 and 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/47\">",
"     47",
"    </a>",
"    ]. Among the 144,737 patients referred for nonacute indications, approximately 50 percent were classified as appropriate, 38 percent as uncertain, and 12 percent as inappropriate. The principle reasons for inappropriate PCI were absence of angina, low-risk ischemia on noninvasive stress testing, or suboptimal antianginal therapy. It should be noted that due to study design overuse, but not underuse, of PCI was evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BOTH PCI AND CABG VERSUS MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Medicine, Angioplasty, or Surgery Study (MASS) and MASS II trials directly compared PCI, CABG, and medical therapy for the management of stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. However, the conclusions of MASS have uncertain applicability to current practice as it was performed prior to the current era of aggressive antithrombotic regimens (particularly around the time of PCI), the routine use of stenting (often with drug-eluting stents) at the time of PCI, the more frequent use of complete revascularization both with PCI and CABG, aggressive lipid lowering with statins, and a greater awareness of the importance of risk factor intervention.",
"   </p>",
"   <p>",
"    While the same limitations apply to the MASS II trial, patient management was more current than in MASS. MASS II randomly assigned 611 patients with multivessel disease (58 percent had triple vessel disease and 92 percent had left anterior descending artery disease) and stable angina (CCS II or III) to CABG, PCI (with bare-metal stenting in 72 percent and PTCA alone in 28 percent), or relatively aggressive medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients who received CABG had an average of 3.3 vessels bypassed, while patients who underwent PCI had an average of 2.1 vessels dilated, and 73 percent received multivessel PCI. The primary endpoint was freedom from all cause death, MI or refractory angina requiring revascularization.",
"   </p>",
"   <p>",
"    At one year, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Freedom from all cause death, MI, or refractory angina requiring revascularization was significantly lower with PCI than with medical therapy or CABG (76 versus 88 and 93 percent respectively).",
"     </li>",
"     <li>",
"      One-year mortality was significantly lower with medical therapy than with PCI or CABG (1.5 versus 4.5 and 4.0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At five-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Freedom from all-cause death, MI, or refractory angina requiring revascularization was significantly higher with CABG than with medical therapy or PCI (79 versus 64 and 67 percent, respectively).",
"     </li>",
"     <li>",
"      There was no significant difference in survival among the three groups (88 to 92 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At ten-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Freedom from all cause death, MI, or refractory angina requiring revascularization was significantly higher with CABG than with PCI or medical therapy (73 versus 55 versus 49 percent, respectively).",
"     </li>",
"     <li>",
"      There was no significant difference in survival among the three groups (69 to 75 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lack of mortality benefit from intervention supports the findings in COURAGE. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'COURAGE and FAME II trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FACTORS THAT FAVOR REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between revascularization and medical therapy is not clear in some cases. This section will provide some guidance. The relative strengths and weaknesses of PCI and CABG are weighed once a determination has been made that revascularization is appropriate. The choice of revascularization procedure is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The COURAGE trial suggested that optimal medical therapy plus PCI with bare-metal stenting compared to optimal medical therapy alone was associated with equivalent rates of death or MI, fewer revascularization procedures, and initially better control of angina. The exclusion criteria in COURAGE described above largely reflect patients who would be likely to have a survival benefit from revascularization usually with CABG (eg, left main disease, a markedly positive stress test, or LVEF less than 30 percent). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'CABG versus medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     ACCF/AHA/SCAI",
"    </span>",
"    guideline on PCI concluded that the following are reasonable indications for PCI of appropriate lesions to improve symptoms in patients with stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with one or more significant coronary artery stenoses amenable to PCI and unacceptable angina despite guideline-directed medical therapy (GDMT).",
"     </li>",
"     <li>",
"      Patients with one or more significant coronary artery stenoses amenable to PCI and unacceptable angina for whom GDMT cannot be implemented.",
"     </li>",
"     <li>",
"      Patients with previous CABG, one or more significant coronary artery stenoses associated with ischemia, and unacceptable angina despite GDMT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these patients will be better treated with CABG. The choice between PCI and CABG is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Results of noninvasive testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with stable angina should undergo stress testing for risk stratification. Stress-test outcomes such as exercise duration, work load achieved, the severity and extent of ischemia, development of dyspnea, or fall in blood pressure of the test in relation to the patient's daily activity level will affect the decision as to whether to recommend revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H16#H16\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A noninvasive test (usually echocardiography) should also be performed to assess left ventricular function in patients with a prior MI or with known HF. In studies comparing CABG to medical therapy, long-term survival was significantly increased with CABG in patients with a reduced LVEF (35 to 49 percent) and three vessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/13\">",
"     13",
"    </a>",
"    ]. Survival was not improved in such patients with one or two vessel disease. Thus, a reduced LVEF is generally an indication for proceeding to angiography.",
"   </p>",
"   <p>",
"    A separate issue in patients with stable angina and a low LVEF is the possibility of revascularization of viable myocardium to improve left ventricular function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patient preference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient preference after a thorough discussion of the relevant issues becomes important for patients who undergo diagnostic coronary arteriography based upon the findings on noninvasive testing and who are not found to have anatomy that mandates revascularization based upon a survival benefit. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Effects on survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since PCI is performed in most revascularization procedures at the time of diagnostic angiography, the discussion with the patient prior to angiography should emphasize both the",
"    <strong>",
"     benefits",
"    </strong>",
"    of PCI (less angina and a lower likelihood of requiring an intervention in the first few years) and the",
"    <strong>",
"     drawbacks",
"    </strong>",
"    of PCI (the inherent risks of the procedure and the potential problems of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy if a drug-eluting stent is used). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases where the indication for revascularization or the decision for PCI versus CABG is less clear, it is important to have additional discussions with the patient after diagnostic angiography and before proceeding with PCI. In those cases that may be considered for PCI or CABG, we agree with the concept of the &ldquo;Heart Team&rdquo; to fully discuss the risks and benefits of both PCI and CABG as well as optimal medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Results of angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once angiography is performed, the severity and extent of disease will influence the decision as to whether or not intervention is warranted and, if so, whether PCI or CABG should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of a low left ventricular ejection fraction as a factor in determining which patients should be revascularized has been studied. Early studies suggested a benefit for CABG in this group, but more studies have questioned the role of revascularization as well as whether viability testing has value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1041702074\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age alone is not a criterion for exclusion from intervention. There is an increased perioperative morbidity and mortality after coronary surgery in elderly patients compared to younger patients. However, nonrandomized data from some of the larger trials and the APPROACH project and randomized data from the TIME trial suggest long-term benefits from revascularization in appropriately selected elderly patients, including octogenarians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the care of patients with stable ischemic heart disease\", section on 'Considerations in older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263112556\">",
"    <span class=\"h1\">",
"     WHEN TO PERFORM CORONARY ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, the decision between medical therapy and revascularization in patients with stable ischemic heart disease (SIHD) depends on the results of diagnostic coronary angiography. We agree with the following strong recommendations to perform this test made in the 2012",
"    <span class=\"nowrap\">",
"     ACCF/AHA/ACP/AATS/PCNA/SCAI/STS",
"    </span>",
"    guideline for the diagnosis and management of patients with stable ischemic heart disease (SIHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/51/9018/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an initial test in patients who have survived sudden cardiac arrest or potentially life-threatening ventricular arrhythmia or in those who develop symptoms and signs of heart failure.",
"     </li>",
"     <li>",
"      When a patient&rsquo;s clinical characteristics and the results of noninvasive testing indicate a high likelihood of severe ischemic heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also agree with the following weaker recommendations for coronary angiography in patients with SIDH and:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depressed left ventricular systolic function (ejection fraction &lt;50 percent) and moderate risk criteria on noninvasive testing with demonstrable ischemia.",
"     </li>",
"     <li>",
"      Inconclusive prognostic information after noninvasive testing or in patients for whom noninvasive testing is contraindicated or inadequate.",
"     </li>",
"     <li>",
"      An unsatisfactory quality of life due to angina, a left ventricular ejection fraction &gt;50 percent, and intermediate risk criteria on noninvasive testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"       \"Patient information: Cardiac catheterization (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/14/30946?source=see_link\">",
"       \"Patient information: Treatment choices for angina (chest pain) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with coronary heart disease, including those with stable angina, should be treated with aggressive risk factor reduction. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Aggressive risk factor reduction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with stable angina should undergo risk stratification with stress testing, and some need an assessment of left ventricular systolic function. This information is used to determine whether a patient is at high risk, defined as a large amount of viable myocardium at risk (as determined by noninvasive imaging or suggested by a strongly positive treadmill test) or significant underlying left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link&amp;anchor=H94290458#H94290458\">",
"     \"Overview of the care of patients with stable ischemic heart disease\", section on 'Measurement of LV systolic function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend coronary angiography followed by revascularization, to improve survival",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms, for two groups of patients with stable angina (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H6\">",
"     'Effects on survival'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in whom maximal medical therapy has not satisfactorily improved anginal symptoms or who are intolerant of medical therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Relief of angina'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with high-risk criteria and selected patients with intermediate-risk criteria on noninvasive testing, regardless of anginal severity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effects on survival'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with stable angina that is not significantly interfering with the quality of life, and for whom revascularization is not indicated to prolong life, we suggest initial medical therapy rather than immediate revascularization (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). In such patients, patient preference may be important. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Patient preference'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'PCI versus medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/1\">",
"      Moliterno DJ, Elliott JM. Randomized trials of myocardial revascularization. Curr Probl Cardiol 1995; 20:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/2\">",
"      Alderman EL, Kip KE, Whitlow PL, et al. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2004; 44:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/3\">",
"      Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/4\">",
"      Rogers WJ, Coggin CJ, Gersh BJ, et al. Ten-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery. The Coronary Artery Surgery Study (CASS). Circulation 1990; 82:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/5\">",
"      Kirklin JW, Naftel CD, Blackstone EH, Pohost GM. Summary of a consensus concerning death and ischemic events after coronary artery bypass grafting. Circulation 1989; 79:I81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/6\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/7\">",
"      Kaiser GC. CABG: lessons from the randomized trials. Ann Thorac Surg 1986; 42:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/8\">",
"      Murphy ML, Hultgren HN, Detre K, et al. Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study. N Engl J Med 1977; 297:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/9\">",
"      Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. N Engl J Med 1984; 310:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/10\">",
"      Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/11\">",
"      Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med 1984; 311:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/12\">",
"      Myers WO, Schaff HV, Gersh BJ, et al. Improved survival of surgically treated patients with triple vessel coronary artery disease and severe angina pectoris. A report from the Coronary Artery Surgery Study (CASS) registry. J Thorac Cardiovasc Surg 1989; 97:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/13\">",
"      Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985; 312:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/14\">",
"      Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 1990; 82:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/15\">",
"      Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988; 319:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/16\">",
"      Samaha JK, Connor MJ, Tribble R, et al. Natural history of left anterior descending coronary artery obstruction: significance of location of stenoses in medically treated patients. Clin Cardiol 1985; 8:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/17\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/18\">",
"      Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Circulation 1992; 86:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/19\">",
"      Kaiser GC, Davis KB, Fisher LD, et al. Survival following coronary artery bypass grafting in patients with severe angina pectoris (CASS). An observational study. J Thorac Cardiovasc Surg 1985; 89:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/20\">",
"      Weiner DA, Ryan TJ, McCabe CH, et al. Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease. J Am Coll Cardiol 1984; 3:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/21\">",
"      Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation 1998; 98:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/22\">",
"      Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol 1986; 7:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/23\">",
"      Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/24\">",
"      Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982; 66:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/25\">",
"      Elefteriades JA, Morales DL, Gradel C, et al. Results of coronary artery bypass grafting by a single surgeon in patients with left ventricular ejection fractions &lt; or = 30%. Am J Cardiol 1997; 79:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/26\">",
"      Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/27\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/28\">",
"      Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/29\">",
"      Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ 2000; 321:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/30\">",
"      Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005; 111:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/31\">",
"      Rihal CS, Sutton-Tyrrell K, Guo P, et al. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation. Circulation 1999; 100:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/32\">",
"      Burek KA, Sutton-Tyrrell K, Brooks MM, et al. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 1999; 34:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/33\">",
"      Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992; 326:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/34\">",
"      Hartigan PM, Giacomini JC, Folland ED, Parisi AF. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine. Am J Cardiol 1998; 82:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/35\">",
"      Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS. J Am Coll Cardiol 1997; 29:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/36\">",
"      Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997; 350:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/37\">",
"      Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/38\">",
"      Pocock SJ, Henderson RA, Clayton T, et al. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. J Am Coll Cardiol 2000; 35:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/39\">",
"      Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008; 359:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/40\">",
"      Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/41\">",
"      De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012; 367:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/42\">",
"      Boden WE. Which is more enduring--FAME or COURAGE? N Engl J Med 2012; 367:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/43\">",
"      Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/44\">",
"      Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation 2013; 127:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/45\">",
"      Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2009; 53:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/46\">",
"      Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2012; 59:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/47\">",
"      Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. JAMA 2011; 306:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/48\">",
"      Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004; 43:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/49\">",
"      Hueb WA, Bellotti G, de Oliveira SA, et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 1995; 26:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/50\">",
"      Hueb WA, Soares PR, Almeida De Oliveira S, et al. Five-year follow-op of the medicine, angioplasty, or surgery study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation 1999; 100:II107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/51\">",
"      Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/52\">",
"      Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010; 122:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/53\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/54\">",
"      Graham MM, Ghali WA, Faris PD, et al. Survival after coronary revascularization in the elderly. Circulation 2002; 105:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/55\">",
"      TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001; 358:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/56\">",
"      Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003; 289:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/57\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/51/9018/abstract/58\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1557 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9018=[""].join("\n");
var outline_f8_51_9018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AGGRESSIVE RISK FACTOR REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CABG VERSUS MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relief of angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effects on survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Severity of angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Strongly positive stress test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1041701551\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PCI VERSUS MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COURAGE and FAME II trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17364273\">",
"      Compliance with appropriateness criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BOTH PCI AND CABG VERSUS MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FACTORS THAT FAVOR REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Results of noninvasive testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patient preference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Results of angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1041702074\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263112556\">",
"      WHEN TO PERFORM CORONARY ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1557|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/39/19069\" title=\"figure 1\">",
"      Ischemia and death after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24013\" title=\"figure 2A\">",
"      IMA versus vein graft patency after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/46/21229\" title=\"figure 2B\">",
"      Survival advantage of arterial coronary bypass grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=related_link\">",
"      Management of significant proximal left anterior descending coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/14/30946?source=related_link\">",
"      Patient information: Treatment choices for angina (chest pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39737?source=related_link\">",
"      Periprocedural myocardial infarction following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_51_9019="Broad spectrum sunscreens";
var content_f8_51_9019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Broad spectrum sunscreens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Examples of sunscreens containing photostabilized avobenzone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrogena&reg; sunscreens with Helioplex&reg; (eg, Ultra Sheer Dry-Touch Sunblock, Age Shield Sunblock, Waterguard&reg; Kids Sunblock, Fresh Cooling Body Mist Sunblock, Ultra Sheer Body Mist)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aveeno&reg; Continuous Protection&reg; Sunblock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Daylong Extreme*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Examples of&nbsp;sunscreens containing ecamsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        La Roche-Posay&reg; Anthelios SX, Anthelios 15, and Anthelios 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Examples of&nbsp;sunscreens containing zinc oxide and titanium dioxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharmaceutical Specialties Vanicream&trade; SPF 30, Fallene C������TZ&trade; SPF 58, Avene mineral cream SPF 50",
"        <sup>",
"         +",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Available in Europe but not in the United States",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9019=[""].join("\n");
var outline_f8_51_9019=null;
var title_f8_51_9020="Medical screening by BMI category";
var content_f8_51_9020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical screening for children with obesity, by BMI category",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        BMI percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physical examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory tests",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        85th-94th percentile",
"       </td>",
"       <td rowspan=\"2\">",
"        Blood pressure, full exam",
"       </td>",
"       <td>",
"        Fasting lipid profile*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conditional testing for abnormalities in blood glucose or liver function",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        &ge;95th percentile",
"       </td>",
"       <td rowspan=\"3\">",
"        Blood pressure, full exam",
"       </td>",
"       <td>",
"        Fasting lipid profile*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin A1c or fasting glucose level every two years",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALT and AST levels every two years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If results of the fasting lipid profile are normal, we suggest repeating the screening every three to five years. If the results are abnormal, annual monitoring usually is appropriate. (Refer to UpToDate topic on Pediatric prevention of adult cardiovascular disease).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     In this weight category, screening for abnormalities in blood glucose or hemoglobin A1c, AST and ALT is recommended if the patient is 10 years or older, and has one or more of the following risk factors: personal history of elevated blood pressure, lipid levels, tobacco use, or family history of obesity-related diseases (type 2 diabetes, lipid abnormalities, heart disease).",
"     <br/>",
"     &Delta; Hemoglobin A1c is now an accepted approach to screening for diabetes mellitus in adults; a hemoglobin A1c level &ge;6.5 percent on two occasions can be used to diagnose diabetes, and patients with A1c values between 5.7 and 6.4 percent are at high risk for developing diabetes. The utility of hemoglobin A1c as a screening tool in children and adolescents has not been fully evaluated.",
"    </div>",
"    <div class=\"reference\">",
"     Recommendations based on: Krebs NF. Assessment of child and adolescent overweight and obesity. Pediatrics 2007; 120:S193.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9020=[""].join("\n");
var outline_f8_51_9020=null;
var title_f8_51_9021="Significant interactions involving triazoles";
var content_f8_51_9021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of clinically significant pharmacokinetic interactions of triazole antifungals*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Mechanisms",
"      </td>",
"      <td class=\"subtitle1\">",
"       Examples",
"      </td>",
"      <td class=\"subtitle1\">",
"       Effects",
"      </td>",
"      <td class=\"subtitle1\">",
"       Consequences",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommendations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Modifications of antifungal pharmacokinetics by other drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Induction of hepatic CYP",
"      </td>",
"      <td>",
"       Rifampicin (rifampin) or rifabutin and triazole antifungals",
"      </td>",
"      <td>",
"       Significantly reduced antifungal plasma exposure",
"      </td>",
"      <td>",
"       Decreased effectiveness and failure of antifungal therapy",
"      </td>",
"      <td>",
"       <p>",
"        Combination of rifampicin/rifabutin and voriconazole: contraindicated",
"       </p>",
"       <p>",
"        Combination of other triazole antifungal: frequent monitoring for adverse events and toxicity",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Modifications of the pharmacokinetics of other drugs by triazole antifungals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inhibition of hepatic CYP2C9",
"      </td>",
"      <td>",
"       Warfarin and fluconazole or voriconazole",
"      </td>",
"      <td>",
"       PT significantly increased",
"      </td>",
"      <td>",
"       Haemorrhage",
"      </td>",
"      <td>",
"       Regular monitoring of the INR and warfarin dose adjustment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inhibition of CYP and BCRP",
"      </td>",
"      <td>",
"       Lovastatin and itraconazole",
"      </td>",
"      <td>",
"       Significantly increased lovastatin plasma exposure",
"      </td>",
"      <td>",
"       Risk of rhabdomyolysis",
"      </td>",
"      <td>",
"       Combination of lovastatin and itraconazole should be avoided or the dose of HMG-CoA reductase inhibitors (statins) should be reduced",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inhibition of CYP and P-gp",
"      </td>",
"      <td>",
"       Quinidine and itraconazole",
"      </td>",
"      <td>",
"       Significantly increased quinidine plasma exposure",
"      </td>",
"      <td>",
"       Risk of QT interval prolongation, torsade de pointes",
"      </td>",
"      <td>",
"       Close monitoring of serum quinidine concentrations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inhibition of P-gp",
"      </td>",
"      <td>",
"       Digoxin and itraconazole",
"      </td>",
"      <td>",
"       Significantly increased digoxin plasma exposure",
"      </td>",
"      <td>",
"       Neurotoxicity, cardiotoxicity",
"      </td>",
"      <td>",
"       Close monitoring of serum digoxin concentrations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inhibition of UGT",
"      </td>",
"      <td>",
"       Zidovudine and fluconazole",
"      </td>",
"      <td>",
"       Significantly increased zidovudine plasma exposure",
"      </td>",
"      <td>",
"       Risk of zidovudine toxicity (anaemia, nausea and headaches)",
"      </td>",
"      <td>",
"       Close monitoring for symptoms of zidovudine toxicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Two-way interaction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Induction of CYP or UGT by phenytoin and inhibition of CYP3A4 by triazole antifungals",
"      </td>",
"      <td>",
"       Phenytoin and triazole antifungals",
"      </td>",
"      <td>",
"       Significantly reduced antifungal plasma exposure; significantly increased phenytoin plasma exposure",
"      </td>",
"      <td>",
"       Treatment failure of antifungal therapy; risk of phenytoin toxicity",
"      </td>",
"      <td>",
"       <p>",
"        Frequent monitoring of phenytoin concentrations should be performed during coadministration with triazole antifungal, and dose reduction of phenytoin should be considered",
"       </p>",
"       <p>",
"        The dose of oral voriconazole should be doubled during coadministration of phenytoin",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BCRP: breast cancer resistance protein; CYP: cytochrome P450; INR: international normalized ratio; P-gp: P-glycoprotein; PT: prothrombin time; UGT: uridine diphosphate glucuronosyltransferase.",
"     <br>",
"      <br>",
"       * Triazoles include fluconazole, itraconazole, voriconazole, and posaconazole.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nivoix, Y, Leveque, D, Herbrecht, R, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47:779. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9021=[""].join("\n");
var outline_f8_51_9021=null;
var title_f8_51_9022="Rhythm versus rate control AF RACE";
var content_f8_51_9022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Rate control versus rhythm control in RACE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of the RACE trial in which 522 patients with recurrent persistent atrial fibrillation (AF) were randomly assigned to rhythm or rate control. The primary end point was a composite of cardiovascular death, heart failure, thromboembolism, bleeding, pacemaker placement, and antiarrhythmic drug side effects. There was an almost significant trend toward a lower incidence of the primary end point with rate control (17.2 versus 22.6 percent with rhythm control, hazard ratio 0.73, 90 percent CI 0.53 to 1.01).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Van Gelder IC, Hagens VE, Bosker HA, et al. N Engl J Med 2002; 347:1834.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9022=[""].join("\n");
var outline_f8_51_9022=null;
var title_f8_51_9023="Hemoglobin electrophoresis at alkaline pH";
var content_f8_51_9023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Hemoglobin electrophoresis (alkaline pH)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an example of hemoglobin electrophoresis run at alkaline pH on cellulose acetate. The electrophoretic positions of the more common hemoglobins are shown on the right.",
"    <br>",
"     Lane 1 is a commercial standard containing approximately equal amounts of hemoglobins A, F, S, and C.",
"     <br>",
"      Lanes 2, 3, 4, 6, 8, and 10 are from normal subjects (Hb A only).",
"      <br>",
"       Lanes 7 and 9 are from subjects with sickle cell trait (Hbs A and S).",
"       <br>",
"        Lane 5 is from a subject with homozygous sickle cell anemia (Hbs F and S).",
"        <br>",
"         Lane 11 is from a subject with hemoglobin SC disease (Hbs S and C).",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Electrophoretogram kindly supplied by Dr. Radek Bieniek, Beth Israel Deaconess Medical Center, Boston, MA.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_51_9023=[""].join("\n");
var outline_f8_51_9023=null;
